Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations

Journal of Medicinal Chemistry

Volumn 61, Issue 15, 2018, Pages 6421-6467

  Young, Robert J ^a   Leeson, Paul D ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Paul Leeson Consulting Ltd Malt House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENCHMARKING; EMPLOYMENT; LIPOPHILICITY; REVIEW; RISK ASSESSMENT; ANIMAL; CHEMICAL PHENOMENA; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

ANIMALS; CHEMICAL PHENOMENA; DRUG DISCOVERY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS;

EID: 85048690701     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.8b00180     Document Type: Review

References (306)

1. Macarron, R.; Banks, M. N.; Bojanic, D.; Burns, D. J.; Cirovic, D. A.; Garyantes, T.; Green, D. V.; Hertzberg, R. P.; Janzen, W. P.; Paslay, J. W.; Schopfer, U.; Sittampalam, G. S. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discovery 2011, 10 (3), 188-195, 10.1038/nrd3368
2. Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discovery 2003, 2 (5), 369-378, 10.1038/nrd1086
3. Davis, A.; Keeling, D.; Steele, J.; Tomkinson, N.; Tinker, A. Components of successful lead generation. Curr. Top. Med. Chem. 2005, 5 (4), 421-439, 10.2174/1568026053828411
4. Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discovery 2015, 14 (7), 475-486, 10.1038/nrd4609
5. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25, 10.1016/S0169-409X(96)00423-1
6. Lipinski, C. A. Druglike properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44 (1), 235-249, 10.1016/S1056-8719(00)00107-6
7. Abad-Zapatero, C. A sorcerer's apprentice and the rule of five: from rule-of-thumb to commandment and beyond. Drug Discovery Today 2007, 12 (23-24), 995-997, 10.1016/j.drudis.2007.10.022
8. Morgan, P.; Van Der Graaf, P. H.; Arrowsmith, J.; Feltner, D. E.; Drummond, K. S.; Wegner, C. D.; Street, S. D. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today 2012, 17 (9-10), 419-424, 10.1016/j.drudis.2011.12.020
9. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M. N. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discovery 2014, 13 (6), 419-431, 10.1038/nrd4309
10. Bayliss, M. K.; Butler, J.; Feldman, P. L.; Green, D. V.; Leeson, P. D.; Palovich, M. R.; Taylor, A. J. Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discovery Today 2016, 21 (10), 1719-1727, 10.1016/j.drudis.2016.07.007
11. Morgan, P.; Brown, D. G.; Lennard, S.; Anderton, M. J.; Barrett, J. C.; Eriksson, U.; Fidock, M.; Hamren, B.; Johnson, A.; March, R. E.; Matcham, J.; Mettetal, J.; Nicholls, D. J.; Platz, S.; Rees, S.; Snowden, M. A.; Pangalos, M. N. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discovery 2018, 17 (3), 167-181, 10.1038/nrd.2017.244
12. Brown, A. C.; Fraser, T. R. On the connection between chemical constitution and physiological action; with special reference to the physiological action of the salts of the ammonium bases derived from Strychnia, Brucia, Thebaia, Codeia, Morphia, and Nicotia. J. Anat. Physiol. 1868, 2 (2), 224-242
13. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 2011, 24 (9), 1420-1456, 10.1021/tx200211v
14. Young, R. J. Physical properties in drug design. In Tactics in Contemporary Drug Design; Meanwell, N. A., Ed.; Springer Berlin Heidelberg: Berlin, 2014; pp 1-68.
15. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discovery 2011, 10 (3), 197-208, 10.1038/nrd3367
16. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51 (4), 817-834, 10.1021/jm701122q
17. Gleeson, M. P.; Leeson, P. D.; Waterbeemd, H. v. d. Physicochemical properties and compound quality. In The Handbook of Medicinal Chemistry: Principles and Practice; Davis, A., Ward, S. E., Eds.; The Royal Society of Chemistry, 2015; pp 1-31.
18. Meanwell, N. A. Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements, and compounds in nontraditional drug space. Chem. Res. Toxicol. 2016, 29 (4), 564-616, 10.1021/acs.chemrestox.6b00043
19. Hansch, C.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 1987, 76 (9), 663-687, 10.1002/jps.2600760902
20. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. 1999, 38 (24), 3743-3748, 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U
21. Hann, M. M.; Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8 (3), 255-263, 10.1016/j.cbpa.2004.04.003
22. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41 (3), 856-864, 10.1021/ci000403i
23. Leach, A. R.; Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on. Curr. Opin. Chem. Biol. 2011, 15 (4), 489-496, 10.1016/j.cbpa.2011.05.008
24. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A â€Rule of three' for fragment-based lead discovery?. Drug Discovery Today 2003, 8 (19), 876-877, 10.1016/S1359-6446(03)02831-9
25. Murray, C. W.; Erlanson, D. A.; Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H.; Richmond, N. J. Validity of ligand efficiency metrics. ACS Med. Chem. Lett. 2014, 5 (6), 616-618, 10.1021/ml500146d
26. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discovery 2014, 13 (2), 105-121, 10.1038/nrd4163
27. Valko, K.; Chiarparin, E.; Nunhuck, S.; Montanari, D. In vitro measurement of drug efficiency index to aid early lead optimization. J. Pharm. Sci. 2012, 101 (11), 4155-4169, 10.1002/jps.23305
28. Lovering, F. Escape from flatland 2: complexity and promiscuity. MedChemComm 2013, 4 (3), 515-519, 10.1039/c2md20347b
29. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009, 52, 6752-6756, 10.1021/jm901241e
30. Ritchie, T. J.; Macdonald, S. J. The impact of aromatic ring count on compound developability-Are too many aromatic rings a liability in drug design?. Drug Discovery Today 2009, 14 (21-22), 1011-1020, 10.1016/j.drudis.2009.07.014
31. Ritchie, T. J.; Macdonald, S. J.; Young, R. J.; Pickett, S. D. The impact of aromatic ring count on compound developability: further insights by examining carbo-and hetero-aromatic and-aliphatic ring types. Drug Discovery Today 2011, 16 (3), 164-171, 10.1016/j.drudis.2010.11.014
32. Ritchie, T. J.; Macdonald, S. J. Physicochemical descriptors of aromatic character and their use in drug discovery. J. Med. Chem. 2014, 57 (17), 7206-7215, 10.1021/jm500515d
33. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett. 2009, 19, 2844-2851, 10.1016/j.bmcl.2009.03.109
34. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the golden triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 2009, 19 (19), 5560-5564, 10.1016/j.bmcl.2009.08.045
35. Leach, A. G.; Pilling, E. A.; Rabow, A. A.; Tomasi, S.; Asaad, N.; Buurma, N. J.; Ballard, A.; Narduolo, S. Enantiomeric pairs reveal that key medicinal chemistry parameters vary more than simple physical property based models can explain. MedChemComm 2012, 3 (5), 528-540, 10.1039/c2md20010d
36. Waring, M. J. Lipophilicity in drug discovery. Expert Opin. Drug Discovery 2010, 5 (3), 235-248, 10.1517/17460441003605098
37. Charifson, P. S.; Walters, W. P. Acidic and basic drugs in medicinal chemistry: a perspective. J. Med. Chem. 2014, 57 (23), 9701-9717, 10.1021/jm501000a
38. Leeson, P. D.; Springthorpe, B. The influence of druglike concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6 (11), 881-890, 10.1038/nrd2445
39. Leeson, P. D. Molecular inflation, attrition and the rule of five. Adv. Drug Delivery Rev. 2016, 101 (Suppl. C), 22-33, 10.1016/j.addr.2016.01.018
40. Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. Twenty years on: the impact of fragments on drug discovery. Nat. Rev. Drug Discovery 2016, 15 (9), 605-619, 10.1038/nrd.2016.109
41. Goodnow, R. A., Jr.; Dumelin, C. E.; Keefe, A. D. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat. Rev. Drug Discovery 2017, 16 (2), 131-147, 10.1038/nrd.2016.213
42. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is There a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41 (5), 1308-1315, 10.1021/ci010366a
43. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J. Med. Chem. 2010, 53 (7), 2986-2997, 10.1021/jm100118x
44. Giordanetto, F.; Bostrom, J.; Tyrchan, C. Follow-on drugs: how far should chemists look?. Drug Discovery Today 2011, 16 (15-16), 722-732, 10.1016/j.drudis.2011.05.011
45. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 2006, 49 (10), 2969-2978, 10.1021/jm0512185
46. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discovery 2009, 8 (3), 203-212, 10.1038/nrd2796
47. Leeson, P. D.; Young, R. J. Molecular property design: does everyone get it?. ACS Med. Chem. Lett. 2015, 6 (7), 722-725, 10.1021/acsmedchemlett.5b00157
48. Leeson, P. D.; St-Gallay, S. A. The influence of the "organizational factor" on compound quality in drug discovery. Nat. Rev. Drug Discovery 2011, 10, 749-765, 10.1038/nrd3552
49. Baker, M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discovery 2013, 12 (1), 5-7, 10.1038/nrd3926
50. Hall, R. J.; Mortenson, P. N.; Murray, C. W. Efficient exploration of chemical space by fragment-based screening. Prog. Biophys. Mol. Biol. 2014, 116 (2-3), 82-91, 10.1016/j.pbiomolbio.2014.09.007
51. Reymond, J. L. The chemical space project. Acc. Chem. Res. 2015, 48 (3), 722-730, 10.1021/ar500432k
52. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48 (2), 403-413, 10.1021/jm0495778
53. Ferenczy, G. G.; Keseru, G. M. How are fragments optimized? A retrospective analysis of 145 fragment optimizations. J. Med. Chem. 2013, 56 (6), 2478-2486, 10.1021/jm301851v
54. Ferenczy, G. G.; Keseru, G. M. Thermodynamics guided lead discovery and optimization. Drug Discovery Today 2010, 15 (21-22), 919-932, 10.1016/j.drudis.2010.08.013
55. Freire, E. A thermodynamic approach to the affinity optimization of drug candidates. Chem. Biol. Drug Des. 2009, 74 (5), 468-472, 10.1111/j.1747-0285.2009.00880.x
56. Olsson, T. S.; Williams, M. A.; Pitt, W. R.; Ladbury, J. E. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J. Mol. Biol. 2008, 384 (4), 1002-1017, 10.1016/j.jmb.2008.09.073
57. Franzini, R. M.; Randolph, C. Chemical space of DNA-encoded libraries. J. Med. Chem. 2016, 59 (14), 6629-6644, 10.1021/acs.jmedchem.5b01874
58. Rafferty, M. F. No denying it: medicinal chemistry training is in big trouble. J. Med. Chem. 2016, 59 (24), 10859-10864, 10.1021/acs.jmedchem.6b00741
59. Leeson, P. D.; Davis, A. M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47 (25), 6338-6348, 10.1021/jm049717d
60. Leeson, P. D.; St-Gallay, S. A.; Wenlock, M. C. Impact of ion class and time on oral drug molecular properties. MedChemComm 2011, 2, 91-105, 10.1039/C0MD00157K
61. Hann, M. M. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2011, 2, 349-355, 10.1039/c1md00017a
62. Hann, M. M.; Keseru, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discovery 2012, 11 (5), 355-365, 10.1038/nrd3701
63. Brown, D. G.; Bostrom, J. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?. J. Med. Chem. 2016, 59 (10), 4443-4458, 10.1021/acs.jmedchem.5b01409
64. Abad-Zapatero, C. Ligand efficiency indices for effective drug discovery. Expert Opin. Drug Discovery 2007, 2 (4), 469-488, 10.1517/17460441.2.4.469
65. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9 (10), 430-431, 10.1016/S1359-6446(04)03069-7
66. Kenny, P. W.; Leitao, A.; Montanari, C. A. Ligand efficiency metrics considered harmful. J. Comput.-Aided Mol. Des. 2014, 28 (7), 699-710, 10.1007/s10822-014-9757-8
67. Shultz, M. D. Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters. Bioorg. Med. Chem. Lett. 2013, 23, 5980-5991, 10.1016/j.bmcl.2013.08.029
68. Shultz, M. D. Improving the plausibility of success with inefficient metrics. ACS Med. Chem. Lett. 2014, 5 (1), 2-5, 10.1021/ml4004638
69. Mortenson, P. N.; Murray, C. W. Assessing the lipophilicity of fragments and early hits. J. Comput.-Aided Mol. Des. 2011, 25 (7), 663-667, 10.1007/s10822-011-9435-z
70. Reynolds, C. H.; Reynolds, R. C. Group additivity in ligand binding affinity: an alternative approach to ligand efficiency. J. Chem. Inf. Model. 2017, 57 (12), 3086-3093, 10.1021/acs.jcim.7b00381
71. Shultz, M. D. The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. Bioorg. Med. Chem. Lett. 2013, 23, 5992-6000, 10.1016/j.bmcl.2013.08.030
72. Tarcsay, A.; Nyiri, K.; Keseru, G. M. Impact of lipophilic efficiency on compound quality. J. Med. Chem. 2012, 55 (3), 1252-1260, 10.1021/jm201388p
73. Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med. Chem. 2013, 5, 113-115, 10.4155/fmc.12.208
74. Williams, G.; Ferenczy, G. G.; Ulander, J.; Keseru, G. M. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery. Drug Discovery Today 2017, 22 (4), 681-689, 10.1016/j.drudis.2016.11.019
75. Wenlock, M. C. Profiling the estimated plasma concentrations of 215 marketed oral drugs. MedChemComm 2016, 7 (4), 706-719, 10.1039/C5MD00583C
76. Valko, K. L.; Teague, S. P.; Pidgeon, C. In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery. ADMET DMPK 2017, 5 (1), 14-38, 10.5599/admet.5.1.373
77. McTigue, M.; Murray, B. W.; Chen, J. H.; Deng, Y. L.; Solowiej, J.; Kania, R. S. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (45), 18281-18289, 10.1073/pnas.1207759109
78. Klaeger, S.; Heinzlmeir, S.; Wilhelm, M.; Polzer, H.; Vick, B.; Koenig, P.-A.; Reinecke, M.; Ruprecht, B.; Petzoldt, S.; Meng, C.; Zecha, J.; Reiter, K.; Qiao, H.; Helm, D.; Koch, H.; Schoof, M.; Canevari, G.; Casale, E.; Depaolini, S. R.; Feuchtinger, A.; Wu, Z.; Schmidt, T.; Rueckert, L.; Becker, W.; Huenges, J.; Garz, A.-K.; Gohlke, B.-O.; Zolg, D. P.; Kayser, G.; Vooder, T.; Preissner, R.; Hahne, H.; ToÌnisson, N.; Kramer, K.; Götze, K.; Bassermann, F.; Schlegl, J.; Ehrlich, H.-C.; Aiche, S.; Walch, A.; Greif, P. A.; Schneider, S.; Felder, E. R.; Ruland, J.; Médard, G.; Jeremias, I.; Spiekermann, K.; Kuster, B. The target landscape of clinical kinase drugs. Science 2017, 358 (6367), eaan4368, 10.1126/science.aan4368
79. Young, R. J. The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?. Bioorg. Med. Chem. Lett. 2011, 21 (21), 6228-6235, 10.1016/j.bmcl.2011.08.119
80. Arnott, J. A.; Planey, S. L. The influence of lipophilicity in drug discovery and design. Expert Opin. Drug Discovery 2012, 7 (10), 863-875, 10.1517/17460441.2012.714363
81. Hill, A. P.; Young, R. J. Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug Discovery Today 2010, 15 (15-16), 648-655, 10.1016/j.drudis.2010.05.016
82. Young, R. J.; Green, D. V.; Luscombe, C. N.; Hill, A. P. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today 2011, 16 (17-18), 822-830, 10.1016/j.drudis.2011.06.001
83. Mannhold, R.; Poda, G. I.; Ostermann, C.; Tetko, I. V. Calculation of molecular lipophilicity: state-of-the-art and comparison of logP methods on more than 96,000 compounds. J. Pharm. Sci. 2009, 98, 861-893, 10.1002/jps.21494
84. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP methods. J. Phys. Chem. A 1998, 102 (21), 3762-3772, 10.1021/jp980230o
85. Wildman, S. A.; Crippen, G. M. Prediction of physicochemical parameters by atomic contributions. J. Chem. Inf. Comput. Sci. 1999, 39 (5), 868-873, 10.1021/ci990307l
86. Christmann-Franck, S.; Cravo, D.; Abad-Zapatero, C. Time-trajectories in efficiency maps as effective guides for drug discovery efforts. Mol. Inf. 2011, 30 (2-3), 137-144, 10.1002/minf.201000158
87. Cramer, R. D. BC(DEF) parameters. 1. The intrinsic dimensionality of intermolecular interactions in the liquid state. J. Am. Chem. Soc. 1980, 102 (6), 1837-1849, 10.1021/ja00526a013
88. Abraham, M. H.; Chadha, H. S.; Whiting, G. S.; Mitchell, R. C. Hydrogen bonding. 32. An analysis of water-octanol and water-alkane partitioning and the delta log P parameter of Seiler. J. Pharm. Sci. 1994, 83 (8), 1085-1100, 10.1002/jps.2600830806
89. Pye, C. R.; Hewitt, W. M.; Schwochert, J.; Haddad, T. D.; Townsend, C. E.; Etienne, L.; Lao, Y.; Limberakis, C.; Furukawa, A.; Mathiowetz, A. M.; Price, D. A.; Liras, S.; Lokey, R. S. Nonclassical size dependence of permeation defines bounds for passive adsorption of large drug molecules. J. Med. Chem. 2017, 60 (5), 1665-1672, 10.1021/acs.jmedchem.6b01483
90. Wood, A.; Armour, D. The Discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. In Progress in Medicinal Chemistry; King, F. D., Lawton, G., Eds.; Elsevier, 2005; Vol. 43, pp 239-271, DOI: 10.1016/S0079-6468(05)43007-6.
91. Stupple, P. A.; Batchelor, D. V.; Corless, M.; Dorr, P. K.; Ellis, D.; Fenwick, D. R.; Galan, S. R.; Jones, R. M.; Mason, H. J.; Middleton, D. S.; Perros, M.; Perruccio, F.; Platts, M. Y.; Pryde, D. C.; Rodrigues, D.; Smith, N. N.; Stephenson, P. T.; Webster, R.; Westby, M.; Wood, A. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydr o-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J. Med. Chem. 2011, 54 (1), 67-77, 10.1021/jm100978n
92. Shen, D. M.; Shu, M.; Willoughby, C. A.; Shah, S.; Lynch, C. L.; Hale, J. J.; Mills, S. G.; Chapman, K. T.; Malkowitz, L.; Springer, M. S.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Lyons, K.; Pivnichny, J. V.; Kwei, G. Y.; Carella, A.; Carver, G.; Holmes, K.; Schleif, W. A.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M. D.; Emini, E. A. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. Bioorg. Med. Chem. Lett. 2004, 14 (4), 941-945, 10.1016/j.bmcl.2003.12.005
93. Kumar, S.; Kwei, G. Y.; Poon, G. K.; Iliff, S. A.; Wang, Y.; Chen, Q.; Franklin, R. B.; Didolkar, V.; Wang, R. W.; Yamazaki, M.; Chiu, S. H.; Lin, J. H.; Pearson, P. G.; Baillie, T. A. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J. Pharmacol. Exp. Ther. 2003, 304 (3), 1161-1171, 10.1124/jpet.102.045096
94. Kazmierski, W. M.; Danehower, S.; Duan, M.; Ferris, R. G.; Elitzin, V.; Minick, D.; Sharp, M.; Stewart, E.; Villeneuve, M. Biological and structural characterization of rotamers of C-C chemokine receptor type 5 (CCR5) inhibitor GSK214096. ACS Med. Chem. Lett. 2014, 5 (12), 1296-1299, 10.1021/ml5004124
95. Cumming, J. G.; Tucker, H.; Oldfield, J.; Fielding, C.; Highton, A.; Faull, A.; Wild, M.; Brown, D.; Wells, S.; Shaw, J. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 2012, 22 (4), 1655-1659, 10.1016/j.bmcl.2011.12.117
96. Cornwell, P. D.; Ulrich, R. G. Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles. Toxicol. Pathol. 2007, 35 (4), 576-588, 10.1080/01926230701383194
97. Gerlag, D. M.; Hollis, S.; Layton, M.; Vencovsky, J.; Szekanecz, Z.; Braddock, M.; Tak, P. P. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010, 62 (11), 3154-3160, 10.1002/art.27652
98. Lemoine, R. C.; Wanner, J. Small molecule antagonists of the chemokine receptor CCR5. Curr. Top. Med. Chem. 2010, 10 (13), 1299-1338, 10.2174/156802610791561219
99. Pease, J.; Horuk, R. Chemokine receptor antagonists. J. Med. Chem. 2012, 55 (22), 9363-9392, 10.1021/jm300682j
100. Armour, D.; de Groot, M. J.; Edwards, M.; Perros, M.; Price, D. A.; Stammen, B. L.; Wood, A. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies. ChemMedChem 2006, 1 (7), 706-709, 10.1002/cmdc.200600031
101. Price, D. A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B. L.; Wood, A. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett. 2006, 16 (17), 4633-4637, 10.1016/j.bmcl.2006.06.012
102. Abel, S.; Russell, D.; Whitlock, L. A.; Ridgway, C. E.; Nedderman, A. N.; Walker, D. K. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br. J. Clin. Pharmacol. 2008, 65 (Suppl. 1), 60-67, 10.1111/j.1365-2125.2008.03137.x
103. Swinney, D. C.; Beavis, P.; Chuang, K. T.; Zheng, Y.; Lee, I.; Gee, P.; Deval, J.; Rotstein, D. M.; Dioszegi, M.; Ravendran, P.; Zhang, J.; Sankuratri, S.; Kondru, R.; Vauquelin, G. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br. J. Pharmacol. 2014, 171 (14), 3364-3375, 10.1111/bph.12683
104. Tan, Q.; Zhu, Y.; Li, J.; Chen, Z.; Han, G. W.; Kufareva, I.; Li, T.; Ma, L.; Fenalti, G.; Li, J.; Zhang, W.; Xie, X.; Yang, H.; Jiang, H.; Cherezov, V.; Liu, H.; Stevens, R. C.; Zhao, Q.; Wu, B. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013, 341 (6152), 1387-1390, 10.1126/science.1241475
105. Burrows, J. N.; Cumming, J. G.; Fillery, S. M.; Hamlin, G. A.; Hudson, J. A.; Jackson, R. J.; McLaughlin, S.; Shaw, J. S. Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. Bioorg. Med. Chem. Lett. 2005, 15 (1), 25-28, 10.1016/j.bmcl.2004.10.044
106. Cumming, J. G.; Cooper, A. E.; Grime, K.; Logan, C. J.; McLaughlin, S.; Oldfield, J.; Shaw, J. S.; Tucker, H.; Winter, J.; Whittaker, D. Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides. Bioorg. Med. Chem. Lett. 2005, 15 (22), 5012-5015, 10.1016/j.bmcl.2005.08.014
107. Cumming, J. G.; Brown, S. J.; Cooper, A. E.; Faull, A. W.; Flynn, A. P.; Grime, K.; Oldfield, J.; Shaw, J. S.; Shepherd, E.; Tucker, H.; Whittaker, D. Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides. Bioorg. Med. Chem. Lett. 2006, 16 (13), 3533-3536, 10.1016/j.bmcl.2006.03.089
108. Dorn, C. P.; Finke, P. E.; Oates, B.; Budhu, R. J.; Mills, S. G.; MacCoss, M.; Malkowitz, L.; Springer, M. S.; Daugherty, B. L.; Gould, S. L.; DeMartino, J. A.; Siciliano, S. J.; Carella, A.; Carver, G.; Holmes, K.; Danzeisen, R.; Hazuda, D.; Kessler, J.; Lineberger, J.; Miller, M.; Schleif, W. A.; Emini, E. A. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11 (2), 259-264, 10.1016/S0960-894X(00)00637-5
109. Kazmierski, W. M.; Aquino, C.; Chauder, B. A.; Deanda, F.; Ferris, R.; Jones-Hertzog, D. K.; Kenakin, T.; Koble, C. S.; Watson, C.; Wheelan, P.; Yang, H.; Youngman, M. Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. J. Med. Chem. 2008, 51 (20), 6538-6546, 10.1021/jm800598a
110. Kazmierski, W. M.; Anderson, D. L.; Aquino, C.; Chauder, B. A.; Duan, M.; Ferris, R.; Kenakin, T.; Koble, C. S.; Lang, D. G.; McIntyre, M. S.; Peckham, J.; Watson, C.; Wheelan, P.; Spaltenstein, A.; Wire, M. B.; Svolto, A.; Youngman, M. Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J. Med. Chem. 2011, 54 (11), 3756-3767, 10.1021/jm200279v
111. Perzborn, E.; Roehrig, S.; Straub, A.; Kubitza, D.; Misselwitz, F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discovery 2011, 10 (1), 61-75, 10.1038/nrd3185
112. Wong, P. C.; Pinto, D. J.; Zhang, D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thrombolysis 2011, 31 (4), 478-492, 10.1007/s11239-011-0551-3
113. Becker, R. C.; Alexander, J.; Dyke, C. K.; Harrington, R. A. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb. Haemostasis 2004, 92 (6), 1182-1193, 10.1160/TH04-05-0289
114. Zhang, P.; Huang, W.; Wang, L.; Bao, L.; Jia, Z. J.; Bauer, S. M.; Goldman, E. A.; Probst, G. D.; Song, Y.; Su, T.; Fan, J.; Wu, Y.; Li, W.; Woolfrey, J.; Sinha, U.; Wong, P. W.; Edwards, S. T.; Arfsten, A. E.; Clizbe, L. A.; Kanter, J.; Pandey, A.; Park, G.; Hutchaleelaha, A.; Lambing, J. L.; Hollenbach, S. J.; Scarborough, R. M.; Zhu, B. Y. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett. 2009, 19 (8), 2179-2185, 10.1016/j.bmcl.2009.02.111
115. Chan, C.; Borthwick, A. D.; Brown, D.; Burns-Kurtis, C. L.; Campbell, M.; Chaudry, L.; Chung, C. W.; Convery, M. A.; Hamblin, J. N.; Johnstone, L.; Kelly, H. A.; Kleanthous, S.; Patikis, A.; Patel, C.; Pateman, A. J.; Senger, S.; Shah, G. P.; Toomey, J. R.; Watson, N. S.; Weston, H. E.; Whitworth, C.; Young, R. J.; Zhou, P. Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfon amides. J. Med. Chem. 2007, 50 (7), 1546-1557, 10.1021/jm060870c
116. Watson, N. S.; Adams, C.; Belton, D.; Brown, D.; Burns-Kurtis, C. L.; Chaudry, L.; Chan, C.; Convery, M. A.; Davies, D. E.; Exall, A. M.; Harling, J. D.; Irvine, S.; Irving, W. R.; Kleanthous, S.; McLay, I. M.; Pateman, A. J.; Patikis, A. N.; Roethke, T. J.; Senger, S.; Stelman, G. J.; Toomey, J. R.; West, R. I.; Whittaker, C.; Zhou, P.; Young, R. J. The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs. Bioorg. Med. Chem. Lett. 2011, 21 (6), 1588-1592, 10.1016/j.bmcl.2011.01.129
117. Young, R. J.; Borthwick, A. D.; Brown, D.; Burns-Kurtis, C. L.; Campbell, M.; Chan, C.; Charbaut, M.; Chung, C. W.; Convery, M. A.; Kelly, H. A.; Paul King, N.; Kleanthous, S.; Mason, A. M.; Pateman, A. J.; Patikis, A. N.; Pinto, I. L.; Pollard, D. R.; Senger, S.; Shah, G. P.; Toomey, J. R.; Watson, N. S.; Weston, H. E. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs. Bioorg. Med. Chem. Lett. 2008, 18 (1), 23-27, 10.1016/j.bmcl.2007.11.023
118. Young, R. J.; Borthwick, A. D.; Brown, D.; Burns-Kurtis, C. L.; Campbell, M.; Chan, C.; Charbaut, M.; Convery, M. A.; Diallo, H.; Hortense, E.; Irving, W. R.; Kelly, H. A.; King, N. P.; Kleanthous, S.; Mason, A. M.; Pateman, A. J.; Patikis, A. N.; Pinto, I. L.; Pollard, D. R.; Senger, S.; Shah, G. P.; Toomey, J. R.; Watson, N. S.; Weston, H. E.; Zhou, P. Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs. Bioorg. Med. Chem. Lett. 2008, 18 (1), 28-33, 10.1016/j.bmcl.2007.11.019
119. Kleanthous, S.; Borthwick, A. D.; Brown, D.; Burns-Kurtis, C. L.; Campbell, M.; Chaudry, L.; Chan, C.; Clarte, M. O.; Convery, M. A.; Harling, J. D.; Hortense, E.; Irving, W. R.; Irvine, S.; Pateman, A. J.; Patikis, A. N.; Pinto, I. L.; Pollard, D. R.; Roethka, T. J.; Senger, S.; Shah, G. P.; Stelman, G. J.; Toomey, J. R.; Watson, N. S.; West, R. I.; Whittaker, C.; Zhou, P.; Young, R. J. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs. Bioorg. Med. Chem. Lett. 2010, 20 (2), 618-622, 10.1016/j.bmcl.2009.11.077
120. Watson, N. S.; Brown, D.; Campbell, M.; Chan, C.; Chaudry, L.; Convery, M. A.; Fenwick, R.; Hamblin, J. N.; Haslam, C.; Kelly, H. A.; King, N. P.; Kurtis, C. L.; Leach, A. R.; Manchee, G. R.; Mason, A. M.; Mitchell, C.; Patel, C.; Patel, V. K.; Senger, S.; Shah, G. P.; Weston, H. E.; Whitworth, C.; Young, R. J. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors. Bioorg. Med. Chem. Lett. 2006, 16 (14), 3784-3788, 10.1016/j.bmcl.2006.04.053
121. Bell, A. S.; Palmer, M. J. The discovery of the long-acting PDE5 inhibitor PF-489791 for the treatment of pulmonary hypertension. In Accounts in Drug Discovery: Case Studies in Medicinal Chemistry; Barrish, J., Carter, P., Cheng, P., Zahler, R., Eds.; The Royal Society of Chemistry, 2010; Chapter 8, pp 166-182, DOI: 10.1039/9781849731980-00166.
122. Palmer, M.; Bell, A.; Fox, D.; Brown, D. Design of second generation phosphodiesterase 5 inhibitors. Curr. Top. Med. Chem. 2007, 7 (4), 405-419, 10.2174/156802607779941288
123. Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 1996, 6 (15), 1819-1824, 10.1016/0960-894X(96)00323-X
124. Haning, H.; Niewöhner, U.; Schenke, T.; Es-Sayed, M.; Schmidt, G.; Lampe, T.; Bischoff, E. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12 (6), 865-868, 10.1016/S0960-894X(02)00030-6
125. Daugan, A.; Grondin, P.; Ruault, C.; Le Monnier de Gouville, A. C.; Coste, H.; Kirilovsky, J.; Hyafil, F.; Labaudiniere, R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1′,5′:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J. Med. Chem. 2003, 46 (21), 4525-4532, 10.1021/jm030056e
126. Ghosh, A. K.; Cárdenas, E. L.; Osswald, H. L. The design, development, and evaluation of BACE1 inhibitors for the treatment of Alzheimer's disease. In Alzheimer's Disease II; Wolfe, M. S., Ed.; Springer International Publishing: Cham, Switzerland, 2016; pp 27-85, DOI: 10.1007/7355-2016-16.
127. Oehlrich, D.; Prokopcova, H.; Gijsen, H. J. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg. Med. Chem. Lett. 2014, 24 (9), 2033-2045, 10.1016/j.bmcl.2014.03.025
128. Prati, F.; Bottegoni, G.; Bolognesi, M. L.; Cavalli, A. BACE-1 Inhibitors: from recent single-target molecules to multitarget compounds for Alzheimer's disease. J. Med. Chem. 2018, 61, 619-637, 10.1021/acs.jmedchem.7b00393
129. Geschwindner, S.; Olsson, L. L.; Albert, J. S.; Deinum, J.; Edwards, P. D.; de Beer, T.; Folmer, R. H. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. J. Med. Chem. 2007, 50 (24), 5903-5911, 10.1021/jm070825k
130. Jeppsson, F.; Eketjall, S.; Janson, J.; Karlstrom, S.; Gustavsson, S.; Olsson, L. L.; Radesater, A. C.; Ploeger, B.; Cebers, G.; Kolmodin, K.; Swahn, B. M.; von Berg, S.; Bueters, T.; Falting, J. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J. Biol. Chem. 2012, 287 (49), 41245-41257, 10.1074/jbc.M112.409110
131. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J. Med. Chem. 2007, 50 (24), 5912-5925, 10.1021/jm070829p
132. Scott, J. D.; Li, S. W.; Brunskill, A. P.; Chen, X.; Cox, K.; Cumming, J. N.; Forman, M.; Gilbert, E. J.; Hodgson, R. A.; Hyde, L. A.; Jiang, Q.; Iserloh, U.; Kazakevich, I.; Kuvelkar, R.; Mei, H.; Meredith, J.; Misiaszek, J.; Orth, P.; Rossiter, L. M.; Slater, M.; Stone, J.; Strickland, C. O.; Voigt, J. H.; Wang, G.; Wang, H.; Wu, Y.; Greenlee, W. J.; Parker, E. M.; Kennedy, M. E.; Stamford, A. W. Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-8931)-a beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer's disease. J. Med. Chem. 2016, 59 (23), 10435-10450, 10.1021/acs.jmedchem.6b00307
133. Cumming, J. N.; Smith, E. M.; Wang, L.; Misiaszek, J.; Durkin, J.; Pan, J.; Iserloh, U.; Wu, Y.; Zhu, Z.; Strickland, C.; Voigt, J.; Chen, X.; Kennedy, M. E.; Kuvelkar, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Czarniecki, M. F.; Greenlee, W. J.; McKittrick, B. A.; Parker, E. M.; Stamford, A. W. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg. Med. Chem. Lett. 2012, 22 (7), 2444-2449, 10.1016/j.bmcl.2012.02.013
134. Stamford, A. W.; Scott, J. D.; Li, S. W.; Babu, S.; Tadesse, D.; Hunter, R.; Wu, Y.; Misiaszek, J.; Cumming, J. N.; Gilbert, E. J.; Huang, C.; McKittrick, B. A.; Hong, L.; Guo, T.; Zhu, Z.; Strickland, C.; Orth, P.; Voigt, J. H.; Kennedy, M. E.; Chen, X.; Kuvelkar, R.; Hodgson, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Parker, E. M.; Greenlee, W. J. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Abeta reduction. ACS Med. Chem. Lett. 2012, 3 (11), 897-902, 10.1021/ml3001165
135. Mullard, A. BACE inhibitor bust in Alzheimer trial. Nat. Rev. Drug Discovery 2017, 16 (3), 155, 10.1038/nrd.2017.43
136. Borthwick, J. A.; Ancellin, N.; Bertrand, S. M.; Bingham, R. P.; Carter, P. S.; Chung, C. W.; Churcher, I.; Dodic, N.; Fournier, C.; Francis, P. L.; Hobbs, A.; Jamieson, C.; Pickett, S. D.; Smith, S. E.; Somers, D. O.; Spitzfaden, C.; Suckling, C. J.; Young, R. J. Structurally diverse mitochondrial branched chain aminotransferase (BCATm) leads with varying binding modes identified by fragment screening. J. Med. Chem. 2016, 59 (6), 2452-2467, 10.1021/acs.jmedchem.5b01607
137. Bertrand, S. M.; Ancellin, N.; Beaufils, B.; Bingham, R. P.; Borthwick, J. A.; Boullay, A. B.; Boursier, E.; Carter, P. S.; Chung, C. W.; Churcher, I.; Dodic, N.; Fouchet, M. H.; Fournier, C.; Francis, P. L.; Gummer, L. A.; Herry, K.; Hobbs, A.; Hobbs, C. I.; Homes, P.; Jamieson, C.; Nicodeme, E.; Pickett, S. D.; Reid, I. H.; Simpson, G. L.; Sloan, L. A.; Smith, S. E.; Somers, D. O.; Spitzfaden, C.; Suckling, C. J.; Valko, K.; Washio, Y.; Young, R. J. The discovery of in vivo active mitochondrial branched-chain aminotransferase (BCATm) inhibitors by hybridizing fragment and HTS hits. J. Med. Chem. 2015, 58 (18), 7140-7163, 10.1021/acs.jmedchem.5b00313
138. Deng, H.; Zhou, J.; Sundersingh, F. S.; Summerfield, J.; Somers, D.; Messer, J. A.; Satz, A. L.; Ancellin, N.; Arico-Muendel, C. C.; Sargent Bedard, K. L.; Beljean, A.; Belyanskaya, S. L.; Bingham, R.; Smith, S. E.; Boursier, E.; Carter, P.; Centrella, P. A.; Clark, M. A.; Chung, C. W.; Davie, C. P.; Delorey, J. L.; Ding, Y.; Franklin, G. J.; Grady, L. C.; Herry, K.; Hobbs, C.; Kollmann, C. S.; Morgan, B. A.; Pothier Kaushansky, L. J.; Zhou, Q. Discovery, SAR, and X-ray binding mode study of BCATm inhibitors from a novel DNA-encoded library. ACS Med. Chem. Lett. 2015, 6 (8), 919-924, 10.1021/acsmedchemlett.5b00179
139. Deng, H.; Zhou, J.; Sundersingh, F.; Messer, J. A.; Somers, D. O.; Ajakane, M.; Arico-Muendel, C. C.; Beljean, A.; Belyanskaya, S. L.; Bingham, R.; Blazensky, E.; Boullay, A. B.; Boursier, E.; Chai, J.; Carter, P.; Chung, C. W.; Daugan, A.; Ding, Y.; Herry, K.; Hobbs, C.; Humphries, E.; Kollmann, C.; Nguyen, V. L.; Nicodeme, E.; Smith, S. E.; Dodic, N.; Ancellin, N. Discovery and optimization of potent, selective, and in vivo efficacious 2-aryl benzimidazole BCATm inhibitors. ACS Med. Chem. Lett. 2016, 7 (4), 379-384, 10.1021/acsmedchemlett.5b00389
140. White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J.; Hostomsky, Z.; Maegley, K.; Newell, D. R.; Srinivasan, S.; Golding, B. T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 2000, 43 (22), 4084-4097, 10.1021/jm000950v
141. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C.; Martin, N. M. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 2008, 51 (20), 6581-6591, 10.1021/jm8001263
142. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 2007, 6 (3), 945-956, 10.1158/1535-7163.MCT-06-0552
143. Penning, T. D.; Zhu, G. D.; Gandhi, V. B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E. F.; Donawho, C. K.; Frost, D. J.; Bontcheva-Diaz, V.; Bouska, J. J.; Osterling, D. J.; Olson, A. M.; Marsh, K. C.; Luo, Y.; Giranda, V. L. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem. 2009, 52 (2), 514-523, 10.1021/jm801171j
144. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem 2008, 3 (8), 1179-1180, 10.1002/cmdc.200800132
145. Jones, P.; Wilcoxen, K.; Rowley, M.; Toniatti, C. Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J. Med. Chem. 2015, 58 (8), 3302-3314, 10.1021/jm5018237
146. Wang, B.; Chu, D.; Feng, Y.; Shen, Y.; Aoyagi-Scharber, M.; Post, L. E. Discovery and characterization of (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-te trahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, talazoparib), a novel, highly potent, and orally efficacious poly(ADP-ribose) polymerase-1/2 inhibitor, as an anticancer agent. J. Med. Chem. 2016, 59 (1), 335-357, 10.1021/acs.jmedchem.5b01498
147. de Bono, J.; Ramanathan, R. K.; Mina, L.; Chugh, R.; Glaspy, J.; Rafii, S.; Kaye, S.; Sachdev, J.; Heymach, J.; Smith, D. C.; Henshaw, J. W.; Herriott, A.; Patterson, M.; Curtin, N. J.; Byers, L. A.; Wainberg, Z. A. Phase I, dose-escalation, two-part trial of the PARP Inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discovery 2017, 7 (6), 620-629, 10.1158/2159-8290.CD-16-1250
148. Di Santo, R. Inhibiting the HIV integration process: past, present, and the future. J. Med. Chem. 2014, 57 (3), 539-566, 10.1021/jm400674a
149. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287 (5453), 646-650, 10.1126/science.287.5453.646
150. Summa, V.; Petrocchi, A.; Matassa, V. G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O. G.; Laufer, R.; Monteagudo, E.; Pace, P. 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem. 2006, 49 (23), 6646-6649, 10.1021/jm060854f
151. Petrocchi, A.; Koch, U.; Matassa, V. G.; Pacini, B.; Stillmock, K. A.; Summa, V. From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. Bioorg. Med. Chem. Lett. 2007, 17 (2), 350-353, 10.1016/j.bmcl.2006.10.054
152. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51 (18), 5843-5855, 10.1021/jm800245z
153. Johns, B. A.; Kawasuji, T.; Weatherhead, J. G.; Taishi, T.; Temelkoff, D. P.; Yoshida, H.; Akiyama, T.; Taoda, Y.; Murai, H.; Kiyama, R.; Fuji, M.; Tanimoto, N.; Jeffrey, J.; Foster, S. A.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Johnson, M. N.; Garvey, E. P.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J. Med. Chem. 2013, 56 (14), 5901-5916, 10.1021/jm400645w
154. Kawasuji, T.; Johns, B. A.; Yoshida, H.; Weatherhead, J. G.; Akiyama, T.; Taishi, T.; Taoda, Y.; Mikamiyama-Iwata, M.; Murai, H.; Kiyama, R.; Fuji, M.; Tanimoto, N.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Garvey, E. P.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J. Med. Chem. 2013, 56 (3), 1124-1135, 10.1021/jm301550c
155. Kawasuji, T.; Johns, B. A.; Yoshida, H.; Taishi, T.; Taoda, Y.; Murai, H.; Kiyama, R.; Fuji, M.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. J. Med. Chem. 2012, 55 (20), 8735-8744, 10.1021/jm3010459
156. Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J. Med. Chem. 2009, 52 (15), 4869-4882, 10.1021/jm900460z
157. Satz, A. L.; Cai, J.; Chen, Y.; Goodnow, R.; Gruber, F.; Kowalczyk, A.; Petersen, A.; Naderi-Oboodi, G.; Orzechowski, L.; Strebel, Q. DNA compatible multistep synthesis and applications to DNA encoded libraries. Bioconjugate Chem. 2015, 26 (8), 1623-1632, 10.1021/acs.bioconjchem.5b00239
158. Petersen, L. K.; Blakskjær, P.; Chaikuad, A.; Christensen, A. B.; Dietvorst, J.; Holmkvist, J.; Knapp, S.; Kořínek, M.; Larsen, L. K.; Pedersen, A. E.; Röhm, S.; Sløk, F. A.; Hansen, N. J. V. Novel p38α MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library. MedChemComm 2016, 7 (7), 1332-1339, 10.1039/C6MD00241B
159. Mullard, A. The drug-maker's guide to the galaxy. Nature 2017, 549 (7673), 445-447, 10.1038/549445a
160. Harris, P. A.; Berger, S. B.; Jeong, J. U.; Nagilla, R.; Bandyopadhyay, D.; Campobasso, N.; Capriotti, C. A.; Cox, J. A.; Dare, L.; Dong, X.; Eidam, P. M.; Finger, J. N.; Hoffman, S. J.; Kang, J.; Kasparcova, V.; King, B. W.; Lehr, R.; Lan, Y.; Leister, L. K.; Lich, J. D.; MacDonald, T. T.; Miller, N. A.; Ouellette, M. T.; Pao, C. S.; Rahman, A.; Reilly, M. A.; Rendina, A. R.; Rivera, E. J.; Schaeffer, M. C.; Sehon, C. A.; Singhaus, R. R.; Sun, H. H.; Swift, B. A.; Totoritis, R. D.; Vossenkamper, A.; Ward, P.; Wisnoski, D. D.; Zhang, D.; Marquis, R. W.; Gough, P. J.; Bertin, J. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J. Med. Chem. 2017, 60 (4), 1247-1261, 10.1021/acs.jmedchem.6b01751
161. Harris, P. A.; King, B. W.; Bandyopadhyay, D.; Berger, S. B.; Campobasso, N.; Capriotti, C. A.; Cox, J. A.; Dare, L.; Dong, X.; Finger, J. N.; Grady, L. C.; Hoffman, S. J.; Jeong, J. U.; Kang, J.; Kasparcova, V.; Lakdawala, A. S.; Lehr, R.; McNulty, D. E.; Nagilla, R.; Ouellette, M. T.; Pao, C. S.; Rendina, A. R.; Schaeffer, M. C.; Summerfield, J. D.; Swift, B. A.; Totoritis, R. D.; Ward, P.; Zhang, A.; Zhang, D.; Marquis, R. W.; Bertin, J.; Gough, P. J. DNA-Encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J. Med. Chem. 2016, 59 (5), 2163-2178, 10.1021/acs.jmedchem.5b01898
162. Vandenabeele, P.; Grootjans, S.; Callewaert, N.; Takahashi, N. Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ. 2013, 20 (2), 185-187, 10.1038/cdd.2012.151
163. Wang, K.; Li, J.; Degterev, A.; Hsu, E.; Yuan, J.; Yuan, C. Structure-activity relationship analysis of a novel necroptosis inhibitor, necrostatin-5. Bioorg. Med. Chem. Lett. 2007, 17 (5), 1455-1465, 10.1016/j.bmcl.2006.11.056
164. Degterev, A.; Hitomi, J.; Germscheid, M.; Ch'en, I. L.; Korkina, O.; Teng, X.; Abbott, D.; Cuny, G. D.; Yuan, C.; Wagner, G.; Hedrick, S. M.; Gerber, S. A.; Lugovskoy, A.; Yuan, J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008, 4, 313-321, 10.1038/nchembio.83
165. Harris, P. A.; Bandyopadhyay, D.; Berger, S. B.; Campobasso, N.; Capriotti, C. A.; Cox, J. A.; Dare, L.; Finger, J. N.; Hoffman, S. J.; Kahler, K. M.; Lehr, R.; Lich, J. D.; Nagilla, R.; Nolte, R. T.; Ouellette, M. T.; Pao, C. S.; Schaeffer, M. C.; Smallwood, A.; Sun, H. H.; Swift, B. A.; Totoritis, R. D.; Ward, P.; Marquis, R. W.; Bertin, J.; Gough, P. J. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med. Chem. Lett. 2013, 4 (12), 1238-1243, 10.1021/ml400382p
166. Xing, L. Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase 2016, 4 (1), 24-30, 10.4081/mk.2015.5508
167. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A.; Jhoti, H. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48 (2), 414-426, 10.1021/jm049575n
168. Selness, S. R.; Devraj, R. V.; Monahan, J. B.; Boehm, T. L.; Walker, J. K.; Devadas, B.; Durley, R. C.; Kurumbail, R.; Shieh, H.; Xing, L.; Hepperle, M.; Rucker, P. V.; Jerome, K. D.; Benson, A. G.; Marrufo, L. D.; Madsen, H. M.; Hitchcock, J.; Owen, T. J.; Christie, L.; Promo, M. A.; Hickory, B. S.; Alvira, E.; Naing, W.; Blevis-Bal, R. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 2009, 19 (20), 5851-5856, 10.1016/j.bmcl.2009.08.082
169. Graneto, M. J.; Kurumbail, R. G.; Vazquez, M. L.; Shieh, H. S.; Pawlitz, J. L.; Williams, J. M.; Stallings, W. C.; Geng, L.; Naraian, A. S.; Koszyk, F. J.; Stealey, M. A.; Xu, X. D.; Weier, R. M.; Hanson, G. J.; Mourey, R. J.; Compton, R. P.; Mnich, S. J.; Anderson, G. D.; Monahan, J. B.; Devraj, R. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase. J. Med. Chem. 2007, 50 (23), 5712-5719, 10.1021/jm0611915
170. Walker, J. K.; Selness, S. R.; Devraj, R. V.; Hepperle, M. E.; Naing, W.; Shieh, H.; Kurambail, R.; Yang, S.; Flynn, D. L.; Benson, A. G.; Messing, D. M.; Dice, T.; Kim, T.; Lindmark, R. J.; Monahan, J. B.; Portanova, J. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2010, 20 (8), 2634-2638, 10.1016/j.bmcl.2010.02.047
171. Aston, N. M.; Bamborough, P.; Buckton, J. B.; Edwards, C. D.; Holmes, D. S.; Jones, K. L.; Patel, V. K.; Smee, P. A.; Somers, D. O.; Vitulli, G.; Walker, A. L. p38Alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J. Med. Chem. 2009, 52 (20), 6257-6269, 10.1021/jm9004779
172. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Luedtke, G. R.; Liang, X.; Lim, D.; Xu, Y.-j.; Laney, M.; Liu, D. Y.; Schreiner, G. F.; Lewicki, J. A.; Dugar, S. Indole-based heterocyclic inhibitors of p38α MAP kinase: designing a conformationally restricted analogue. Bioorg. Med. Chem. Lett. 2003, 13 (18), 3087-3090, 10.1016/S0960-894X(03)00653-X
173. Duffy, J. P.; Harrington, E. M.; Salituro, F. G.; Cochran, J. E.; Green, J.; Gao, H.; Bemis, G. W.; Evindar, G.; Galullo, V. P.; Ford, P. J.; Germann, U. A.; Wilson, K. P.; Bellon, S. F.; Chen, G.; Taslimi, P.; Jones, P.; Huang, C.; Pazhanisamy, S.; Wang, Y. M.; Murcko, M. A.; Su, M. S. The Discovery of VX-745: A novel and selective p38alpha kinase inhibitor. ACS Med. Chem. Lett. 2011, 2 (10), 758-763, 10.1021/ml2001455
174. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9 (4), 268-272, 10.1038/nsb770
175. Angell, R. M.; Bamborough, P.; Cleasby, A.; Cockerill, S. G.; Jones, K. L.; Mooney, C. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 1: discovery and binding mode. Bioorg. Med. Chem. Lett. 2008, 18 (1), 318-323, 10.1016/j.bmcl.2007.10.076
176. Angell, R. M.; Angell, T. D.; Bamborough, P.; Brown, D.; Brown, M.; Buckton, J. B.; Cockerill, S. G.; Edwards, C. D.; Jones, K. L.; Longstaff, T.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L.; Willson, M. Biphenyl amide p38 kinase inhibitors 2: optimisation and SAR. Bioorg. Med. Chem. Lett. 2008, 18 (1), 324-328, 10.1016/j.bmcl.2007.10.043
177. Angell, R.; Aston, N. M.; Bamborough, P.; Buckton, J. B.; Cockerill, S.; deBoeck, S. J.; Edwards, C. D.; Holmes, D. S.; Jones, K. L.; Laine, D. I.; Patel, S.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 3: improvement of cellular and in vivo activity. Bioorg. Med. Chem. Lett. 2008, 18 (15), 4428-4432, 10.1016/j.bmcl.2008.06.048
178. Angell, R. M.; Angell, T. D.; Bamborough, P.; Bamford, M. J.; Chung, C. W.; Cockerill, S. G.; Flack, S. S.; Jones, K. L.; Laine, D. I.; Longstaff, T.; Ludbrook, S.; Pearson, R.; Smith, K. J.; Smee, P. A.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg. Med. Chem. Lett. 2008, 18 (15), 4433-4437, 10.1016/j.bmcl.2008.06.028
179. Selness, S. R.; Devraj, R. V.; Devadas, B.; Walker, J. K.; Boehm, T. L.; Durley, R. C.; Shieh, H.; Xing, L.; Rucker, P. V.; Jerome, K. D.; Benson, A. G.; Marrufo, L. D.; Madsen, H. M.; Hitchcock, J.; Owen, T. J.; Christie, L.; Promo, M. A.; Hickory, B. S.; Alvira, E.; Naing, W.; Blevis-Bal, R.; Messing, D.; Yang, J.; Mao, M. K.; Yalamanchili, G.; Vonder Embse, R.; Hirsch, J.; Saabye, M.; Bonar, S.; Webb, E.; Anderson, G.; Monahan, J. B. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2011, 21 (13), 4066-4071, 10.1016/j.bmcl.2011.04.121
180. Finlay, M. R.; Anderton, M.; Ashton, S.; Ballard, P.; Bethel, P. A.; Box, M. R.; Bradbury, R. H.; Brown, S. J.; Butterworth, S.; Campbell, A.; Chorley, C.; Colclough, N.; Cross, D. A.; Currie, G. S.; Grist, M.; Hassall, L.; Hill, G. B.; James, D.; James, M.; Kemmitt, P.; Klinowska, T.; Lamont, G.; Lamont, S. G.; Martin, N.; McFarland, H. L.; Mellor, M. J.; Orme, J. P.; Perkins, D.; Perkins, P.; Richmond, G.; Smith, P.; Ward, R. A.; Waring, M. J.; Whittaker, D.; Wells, S.; Wrigley, G. L. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 2014, 57 (20), 8249-8267, 10.1021/jm500973a
181. Cheng, H.; Nair, S. K.; Murray, B. W.; Almaden, C.; Bailey, S.; Baxi, S.; Behenna, D.; Cho-Schultz, S.; Dalvie, D.; Dinh, D. M.; Edwards, M. P.; Feng, J. L.; Ferre, R. A.; Gajiwala, K. S.; Hemkens, M. D.; Jackson-Fisher, A.; Jalaie, M.; Johnson, T. O.; Kania, R. S.; Kephart, S.; Lafontaine, J.; Lunney, B.; Liu, K. K.; Liu, Z.; Matthews, J.; Nagata, A.; Niessen, S.; Ornelas, M. A.; Orr, S. T.; Pairish, M.; Planken, S.; Ren, S.; Richter, D.; Ryan, K.; Sach, N.; Shen, H.; Smeal, T.; Solowiej, J.; Sutton, S.; Tran, K.; Tseng, E.; Vernier, W.; Walls, M.; Wang, S.; Weinrich, S. L.; Xin, S.; Xu, H.; Yin, M. J.; Zientek, M.; Zhou, R.; Kath, J. C. Discovery of 1-{(3R,4R)-3-[({5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants. J. Med. Chem. 2016, 59 (5), 2005-2024, 10.1021/acs.jmedchem.5b01633
182. Planken, S.; Behenna, D. C.; Nair, S. K.; Johnson, T. O.; Nagata, A.; Almaden, C.; Bailey, S.; Ballard, T. E.; Bernier, L.; Cheng, H.; Cho-Schultz, S.; Dalvie, D.; Deal, J. G.; Dinh, D. M.; Edwards, M. P.; Ferre, R. A.; Gajiwala, K. S.; Hemkens, M.; Kania, R. S.; Kath, J. C.; Matthews, J.; Murray, B. W.; Niessen, S.; Orr, S. T.; Pairish, M.; Sach, N. W.; Shen, H.; Shi, M.; Solowiej, J.; Tran, K.; Tseng, E.; Vicini, P.; Wang, Y.; Weinrich, S. L.; Zhou, R.; Zientek, M.; Liu, L.; Luo, Y.; Xin, S.; Zhang, C.; Lafontaine, J. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR. J. Med. Chem. 2017, 60 (7), 3002-3019, 10.1021/acs.jmedchem.6b01894
183. Ward, R. A.; Anderton, M. J.; Ashton, S.; Bethel, P. A.; Box, M.; Butterworth, S.; Colclough, N.; Chorley, C. G.; Chuaqui, C.; Cross, D. A.; Dakin, L. A.; Debreczeni, J. E.; Eberlein, C.; Finlay, M. R.; Hill, G. B.; Grist, M.; Klinowska, T. C.; Lane, C.; Martin, S.; Orme, J. P.; Smith, P.; Wang, F.; Waring, M. J. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 2013, 56 (17), 7025-7048, 10.1021/jm400822z
184. Metz, J. T.; Johnson, E. F.; Soni, N. B.; Merta, P. J.; Kifle, L.; Hajduk, P. J. Navigating the kinome. Nat. Chem. Biol. 2011, 7 (4), 200-202, 10.1038/nchembio.530
185. Niessen, S.; Dix, M. M.; Barbas, S.; Potter, Z. E.; Lu, S.; Brodsky, O.; Planken, S.; Behenna, D.; Almaden, C.; Gajiwala, K. S.; Ryan, K.; Ferre, R.; Lazear, M. R.; Hayward, M. M.; Kath, J. C.; Cravatt, B. F. Proteome-wide map of targets of T790M-EGFR-directed covalent inhibitors. Cell Chem. Biol. 2017, 24 (11), 1388-1400, 10.1016/j.chembiol.2017.08.017
186. Lelais, G.; Epple, R.; Marsilje, T. H.; Long, Y. O.; McNeill, M.; Chen, B.; Lu, W.; Anumolu, J.; Badiger, S.; Bursulaya, B.; DiDonato, M.; Fong, R.; Juarez, J.; Li, J.; Manuia, M.; Mason, D. E.; Gordon, P.; Groessl, T.; Johnson, K.; Jia, Y.; Kasibhatla, S.; Li, C.; Isbell, J.; Spraggon, G.; Bender, S.; Michellys, P. Y. Discovery of (R,E)-N-(7-chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imid azol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers. J. Med. Chem. 2016, 59 (14), 6671-6689, 10.1021/acs.jmedchem.5b01985
187. Chan, B. K.; Hanan, E. J.; Bowman, K. K.; Bryan, M. C.; Burdick, D.; Chan, E.; Chen, Y.; Clausen, S.; Dela Vega, T.; Dotson, J.; Eigenbrot, C.; Elliott, R. L.; Heald, R. A.; Jackson, P. S.; Knight, J. D.; La, H.; Lainchbury, M. D.; Malek, S.; Purkey, H. E.; Schaefer, G.; Schmidt, S.; Seward, E. M.; Sideris, S.; Shao, L.; Wang, S.; Yeap, S. K.; Yen, I.; Yu, C.; Heffron, T. P. Discovery of a noncovalent, mutant-selective epidermal growth factor receptor inhibitor. J. Med. Chem. 2016, 59 (19), 9080-9093, 10.1021/acs.jmedchem.6b00995
188. Xiao, B.; Sanders, M. J.; Carmena, D.; Bright, N. J.; Haire, L. F.; Underwood, E.; Patel, B. R.; Heath, R. B.; Walker, P. A.; Hallen, S.; Giordanetto, F.; Martin, S. R.; Carling, D.; Gamblin, S. J. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 2013, 4, 3017, 10.1038/ncomms4017
189. Lan, P.; Romero, F. A.; Wodka, D.; Kassick, A. J.; Dang, Q.; Gibson, T.; Cashion, D.; Zhou, G.; Chen, Y.; Zhang, X.; Zhang, A.; Li, Y.; Trujillo, M. E.; Shao, Q.; Wu, M.; Xu, S.; He, H.; MacKenna, D.; Staunton, J.; Chapman, K. T.; Weber, A.; Sebhat, I. K.; Makara, G. M. Hit-to-lead optimization and discovery of 5-((5-([1,1′-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzozic acid (MK-3903): a novel class of benzimidazole-based activators of AMP-activated protein kinase. J. Med. Chem. 2017, 60 (21), 9040-9052, 10.1021/acs.jmedchem.7b01344
190. Feng, D.; Biftu, T.; Romero, F. A.; Kekec, A.; Dropinski, J.; Kassick, A.; Xu, S.; Kurtz, M. M.; Gollapudi, A.; Shao, Q.; Yang, X.; Lu, K.; Zhou, G.; Kemp, D.; Myers, R. W.; Guan, H.-P.; Trujillo, M. E.; Li, C.; Weber, A.; Sebhat, I. K. Discovery of MK-8722: A systemic, direct pan-activator of AMP-activated protein kinase. ACS Med. Chem. Lett. 2018, 9 (1), 39-44, 10.1021/acsmedchemlett.7b00417
191. Myers, R. W.; Guan, H. P.; Ehrhart, J.; Petrov, A.; Prahalada, S.; Tozzo, E.; Yang, X.; Kurtz, M. M.; Trujillo, M.; Gonzalez Trotter, D.; Feng, D.; Xu, S.; Eiermann, G.; Holahan, M. A.; Rubins, D.; Conarello, S.; Niu, X.; Souza, S. C.; Miller, C.; Liu, J.; Lu, K.; Feng, W.; Li, Y.; Painter, R. E.; Milligan, J. A.; He, H.; Liu, F.; Ogawa, A.; Wisniewski, D.; Rohm, R. J.; Wang, L.; Bunzel, M.; Qian, Y.; Zhu, W.; Wang, H.; Bennet, B.; LaFranco Scheuch, L.; Fernandez, G. E.; Li, C.; Klimas, M.; Zhou, G.; van Heek, M.; Biftu, T.; Weber, A.; Kelley, D. E.; Thornberry, N.; Erion, M. D.; Kemp, D. M.; Sebhat, I. K. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 2017, 357 (6350), 507-511, 10.1126/science.aah5582
192. Cameron, K. O.; Kung, D. W.; Kalgutkar, A. S.; Kurumbail, R. G.; Miller, R.; Salatto, C. T.; Ward, J.; Withka, J. M.; Bhattacharya, S. K.; Boehm, M.; Borzilleri, K. A.; Brown, J. A.; Calabrese, M.; Caspers, N. L.; Cokorinos, E.; Conn, E. L.; Dowling, M. S.; Edmonds, D. J.; Eng, H.; Fernando, D. P.; Frisbie, R.; Hepworth, D.; Landro, J.; Mao, Y.; Rajamohan, F.; Reyes, A. R.; Rose, C. R.; Ryder, T.; Shavnya, A.; Smith, A. C.; Tu, M.; Wolford, A. C.; Xiao, J. Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy. J. Med. Chem. 2016, 59 (17), 8068-8081, 10.1021/acs.jmedchem.6b00866
193. van De Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44 (9), 1313-1333, 10.1021/jm000407e
194. Kettle, J. G.; Wilson, D. M. Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca. Drug Discovery Today 2016, 21 (10), 1596-1608, 10.1016/j.drudis.2016.06.007
195. Tarcsay, á.; KeseruÌ, G. M. Contributions of molecular properties to drug promiscuity. J. Med. Chem. 2013, 56 (5), 1789-1795, 10.1021/jm301514n
196. Meanwell, N. A. Curing hepatitis C virus infection with direct-acting antiviral agents: the arc of a medicinal chemistry triumph. J. Med. Chem. 2016, 59 (16), 7311-7351, 10.1021/acs.jmedchem.6b00915
197. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y. T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K. C.; Hsieh, Y.; Brisson, J. M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49 (20), 6074-6086, 10.1021/jm060325b
198. Kwong, A. D.; Kauffman, R. S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 2011, 29 (11), 993-1003, 10.1038/nbt.2020
199. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem., Int. Ed. 2003, 42 (12), 1356-1360, 10.1002/anie.200390347
200. Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A. M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J. Med. Chem. 2004, 47 (7), 1605-1608, 10.1021/jm0342414
201. Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S. S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B. L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. J. Am. Chem. Soc. 2008, 130 (14), 4607-4609, 10.1021/ja711120r
202. Rudd, M. T.; McCauley, J. A.; Butcher, J. W.; Romano, J. J.; McIntyre, C. J.; Nguyen, K. T.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B. L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of MK-1220: A macrocyclic inhibitor of hepatitis C virus NS3/4A protease with improved preclinical plasma exposure. ACS Med. Chem. Lett. 2011, 2 (3), 207-212, 10.1021/ml1002426
203. McCauley, J. A.; McIntyre, C. J.; Rudd, M. T.; Nguyen, K. T.; Romano, J. J.; Butcher, J. W.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B. L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Mao, S. S.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J. Med. Chem. 2010, 53 (6), 2443-2463, 10.1021/jm9015526
204. Harper, S.; McCauley, J. A.; Rudd, M. T.; Ferrara, M.; DiFilippo, M.; Crescenzi, B.; Koch, U.; Petrocchi, A.; Holloway, M. K.; Butcher, J. W.; Romano, J. J.; Bush, K. J.; Gilbert, K. F.; McIntyre, C. J.; Nguyen, K. T.; Nizi, E.; Carroll, S. S.; Ludmerer, S. W.; Burlein, C.; DiMuzio, J. M.; Graham, D. J.; McHale, C. M.; Stahlhut, M. W.; Olsen, D. B.; Monteagudo, E.; Cianetti, S.; Giuliano, C.; Pucci, V.; Trainor, N.; Fandozzi, C. M.; Rowley, M.; Coleman, P. J.; Vacca, J. P.; Summa, V.; Liverton, N. J. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 2012, 3 (4), 332-336, 10.1021/ml300017p
205. Rodriguez-Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory-Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J. Viral Hepat. 2016, 23 (8), 614-622, 10.1111/jvh.12527
206. Taylor, J. G.; Appleby, T.; Barauskas, O.; Chen, X.; Dvory-Sobol, H.; Gong, R.; Lee, J.; Nejati, E.; Schultz, B.; Wang, Y.; Yang, C.; Yu, M.; Zipfel, S.; Chan, K. P0899: Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J. Hepatol. 2015, 62, S681, 10.1016/S0168-8278(15)31102-8
207. Lawitz, E. J.; O'Riordan, W. D.; Asatryan, A.; Freilich, B. L.; Box, T. D.; Overcash, J. S.; Lovell, S.; Ng, T. I.; Liu, W.; Campbell, A.; Lin, C. W.; Yao, B.; Kort, J. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob. Agents Chemother. 2016, 60 (3), 1546-1555, 10.1128/AAC.02264-15
208. Rosenquist, A.; Samuelsson, B.; Johansson, P. O.; Cummings, M. D.; Lenz, O.; Raboisson, P.; Simmen, K.; Vendeville, S.; de Kock, H.; Nilsson, M.; Horvath, A.; Kalmeijer, R.; de la Rosa, G.; Beumont-Mauviel, M. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 2014, 57 (5), 1673-1693, 10.1021/jm401507s
209. Pilot-Matias, T.; Tripathi, R.; Cohen, D.; Gaultier, I.; Dekhtyar, T.; Lu, L.; Reisch, T.; Irvin, M.; Hopkins, T.; Pithawalla, R.; Middleton, T.; Ng, T.; McDaniel, K.; Or, Y. S.; Menon, R.; Kempf, D.; Molla, A.; Collins, C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob. Agents Chemother. 2015, 59 (2), 988-997, 10.1128/AAC.04227-14
210. Giordanetto, F.; Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J. Med. Chem. 2014, 57 (2), 278-295, 10.1021/jm400887j
211. Bockus, A. T.; Lexa, K. W.; Pye, C. R.; Kalgutkar, A. S.; Gardner, J. W.; Hund, K. C.; Hewitt, W. M.; Schwochert, J. A.; Glassey, E.; Price, D. A.; Mathiowetz, A. M.; Liras, S.; Jacobson, M. P.; Lokey, R. S. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. 2015, 58 (11), 4581-4589, 10.1021/acs.jmedchem.5b00128
212. Doak, B. C.; Over, B.; Giordanetto, F.; Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 2014, 21 (9), 1115-1142, 10.1016/j.chembiol.2014.08.013
213. Villar, E. A.; Beglov, D.; Chennamadhavuni, S.; Porco, J. A., Jr; Kozakov, D.; Vajda, S.; Whitty, A. How proteins bind macrocycles. Nat. Chem. Biol. 2014, 10, 723-731, 10.1038/nchembio.1584
214. Matsson, P.; Doak, B. C.; Over, B.; Kihlberg, J. Cell permeability beyond the rule of 5. Adv. Drug Delivery Rev. 2016, 101 (Suppl. C), 42-61, 10.1016/j.addr.2016.03.013
215. Telaprevir label. https://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf (accessed February 2, 2018).
216. Belema, M.; Nguyen, V. N.; Bachand, C.; Deon, D. H.; Goodrich, J. T.; James, C. A.; Lavoie, R.; Lopez, O. D.; Martel, A.; Romine, J. L.; Ruediger, E. H.; Snyder, L. B.; St. Laurent, D. R.; Yang, F.; Zhu, J.; Wong, H. S.; Langley, D. R.; Adams, S. P.; Cantor, G. H.; Chimalakonda, A.; Fura, A.; Johnson, B. M.; Knipe, J. O.; Parker, D. D.; Santone, K. S.; Fridell, R. A.; Lemm, J. A.; O'Boyle, D. R., 2nd; Colonno, R. J.; Gao, M.; Meanwell, N. A.; Hamann, L. G. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J. Med. Chem. 2014, 57 (5), 2013-2032, 10.1021/jm401836p
217. Belema, M.; Meanwell, N. A. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J. Med. Chem. 2014, 57 (12), 5057-5071, 10.1021/jm500335h
218. Ivanenkov, Y. A.; Veselov, M. S.; Shakhbazyan, A. G.; Aladinskiy, V. A.; Aladinskaya, A. V.; Yartseva, S. M.; Majouga, A. G.; Vantskul, A. S.; Leonov, S. V.; Ivachtchenko, A. V.; Koteliansky, V. E. A comprehensive insight into the chemical space and ADME features of small molecule NS5A inhibitors. Curr. Top. Med. Chem. 2016, 16 (12), 1372-1382, 10.2174/1568026616666151120113040
219. Nettles, J. H.; Stanton, R. A.; Broyde, J.; Amblard, F.; Zhang, H.; Zhou, L.; Shi, J.; McBrayer, T. R.; Whitaker, T.; Coats, S. J.; Kohler, J. J.; Schinazi, R. F. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J. Med. Chem. 2014, 57 (23), 10031-10043, 10.1021/jm501291c
220. Belema, M.; Lopez, O. D.; Bender, J. A.; Romine, J. L.; St. Laurent, D. R.; Langley, D. R.; Lemm, J. A.; O'Boyle, D. R., 2nd; Sun, J. H.; Wang, C.; Fridell, R. A.; Meanwell, N. A. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J. Med. Chem. 2014, 57 (5), 1643-1672, 10.1021/jm401793m
221. DeGoey, D. A.; Randolph, J. T.; Liu, D.; Pratt, J.; Hutchins, C.; Donner, P.; Krueger, A. C.; Matulenko, M.; Patel, S.; Motter, C. E.; Nelson, L.; Keddy, R.; Tufano, M.; Caspi, D. D.; Krishnan, P.; Mistry, N.; Koev, G.; Reisch, T. J.; Mondal, R.; Pilot-Matias, T.; Gao, Y.; Beno, D. W.; Maring, C. J.; Molla, A.; Dumas, E.; Campbell, A.; Williams, L.; Collins, C.; Wagner, R.; Kati, W. M. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J. Med. Chem. 2014, 57 (5), 2047-2057, 10.1021/jm401398x
222. Krishnan, P.; Beyer, J.; Mistry, N.; Koev, G.; Reisch, T.; DeGoey, D.; Kati, W.; Campbell, A.; Williams, L.; Xie, W.; Setze, C.; Molla, A.; Collins, C.; Pilot-Matias, T. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob. Agents Chemother. 2015, 59 (2), 979-987, 10.1128/AAC.04226-14
223. Link, J. O.; Taylor, J. G.; Xu, L.; Mitchell, M.; Guo, H.; Liu, H.; Kato, D.; Kirschberg, T.; Sun, J.; Squires, N.; Parrish, J.; Keller, T.; Yang, Z. Y.; Yang, C.; Matles, M.; Wang, Y.; Wang, K.; Cheng, G.; Tian, Y.; Mogalian, E.; Mondou, E.; Cornpropst, M.; Perry, J.; Desai, M. C. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 2014, 57 (5), 2033-2046, 10.1021/jm401499g
224. Mogalian, E.; German, P.; Kearney, B. P.; Yang, C. Y.; Brainard, D.; Link, J.; McNally, J.; Han, L.; Ling, J.; Mathias, A. Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob. Agents Chemother. 2017, 61 (5), e02084-16, 10.1128/AAC.02084-16
225. Coburn, C. A.; Meinke, P. T.; Chang, W.; Fandozzi, C. M.; Graham, D. J.; Hu, B.; Huang, Q.; Kargman, S.; Kozlowski, J.; Liu, R.; McCauley, J. A.; Nomeir, A. A.; Soll, R. M.; Vacca, J. P.; Wang, D.; Wu, H.; Zhong, B.; Olsen, D. B.; Ludmerer, S. W. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013, 8 (12), 1930-1940, 10.1002/cmdc.201300343
226. Ng, T. I.; Krishnan, P.; Pilot-Matias, T.; Kati, W.; Schnell, G.; Beyer, J.; Reisch, T.; Lu, L.; Dekhtyar, T.; Irvin, M.; Tripathi, R.; Maring, C.; Randolph, J. T.; Wagner, R.; Collins, C. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob. Agents Chemother. 2017, 61 (5), e02558-16, 10.1128/AAC.02558-16
227. Matsson, P.; Kihlberg, J. How big is too big for cell permeability?. J. Med. Chem. 2017, 60 (5), 1662-1664, 10.1021/acs.jmedchem.7b00237
228. Wakenhut, F.; Tran, T. D.; Pickford, C.; Shaw, S.; Westby, M.; Smith-Burchnell, C.; Watson, L.; Paradowski, M.; Milbank, J.; Stonehouse, D.; Cheung, K.; Wybrow, R.; Daverio, F.; Crook, S.; Statham, K.; Leese, D.; Stead, D.; Adam, F.; Hay, D.; Roberts, L. R.; Chiva, J. Y.; Nichols, C.; Blakemore, D. C.; Goetz, G. H.; Che, Y.; Gardner, I.; Dayal, S.; Pike, A.; Webster, R.; Pryde, D. C. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2. ChemMedChem 2014, 9 (7), 1387-1396, 10.1002/cmdc.201400046
229. DeGoey, D. A.; Chen, H. J.; Cox, P. B.; Wendt, M. D. Beyond the rule of 5: lessons learned from Abbvie's drugs and compound collection. J. Med. Chem. 2017, 10.1021/acs.jmedchem.7b00717
230. Schenk, R. L.; Strasser, A.; Dewson, G. BCL-2: Long and winding path from discovery to therapeutic target. Biochem. Biophys. Res. Commun. 2017, 482 (3), 459-469, 10.1016/j.bbrc.2016.10.100
231. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 2006, 49 (2), 656-663, 10.1021/jm0507532
232. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 2008, 51 (21), 6902-6915, 10.1021/jm800669s
233. Souers, A. J.; Leverson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C. S.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C.-M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202-208, 10.1038/nm.3048
234. Venetoclax label. https://www.accessdata.fda.gov/drugsatfda-docs/label/2016/208573s000lbl.pdf (accessed February 2, 2018).
235. Choo, E. F.; Boggs, J.; Zhu, C.; Lubach, J. W.; Catron, N. D.; Jenkins, G.; Souers, A. J.; Voorman, R. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab. Dispos. 2014, 42 (2), 207-212, 10.1124/dmd.113.055053
236. Salem, A. H.; Agarwal, S. K.; Dunbar, M.; Nuthalapati, S.; Chien, D.; Freise, K. J.; Wong, S. L. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 Inhibitor. J. Clin. Pharmacol. 2016, 56 (11), 1355-1361, 10.1002/jcph.741
237. Doak, B. C.; Zheng, J.; Dobritzsch, D.; Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 2016, 59 (6), 2312-2327, 10.1021/acs.jmedchem.5b01286
238. Kramer, C.; Ting, A.; Zheng, H.; Hert, J.; Schindler, T.; Stahl, M.; Robb, G.; Crawford, J. J.; Blaney, J.; Montague, S.; Leach, A. G.; Dossetter, A. G.; Griffen, E. J. Learning medicinal chemistry absorption, distribution, metabolism, excretion, and toxicity (ADMET) rules from cross-company matched molecular pairs analysis (MMPA). J. Med. Chem. 2017, 10.1021/acs.jmedchem.7b00935
239. Hajduk, P. J.; Sauer, D. R. Statistical analysis of the effects of common chemical substituents on ligand potency. J. Med. Chem. 2008, 51 (3), 553-564, 10.1021/jm070838y
240. Walker, M. A. Improvement in aqueous solubility achieved via small molecular changes. Bioorg. Med. Chem. Lett. 2017, 27 (23), 5100-5108, 10.1016/j.bmcl.2017.09.041
241. Cernak, T.; Dykstra, K. D.; Tyagarajan, S.; Vachal, P.; Krska, S. W. The medicinal chemist's toolbox for late stage functionalization of druglike molecules. Chem. Soc. Rev. 2016, 45 (3), 546-576, 10.1039/C5CS00628G
242. Blakemore, D. C.; Castro, L.; Churcher, I.; Rees, D. C.; Thomas, A. W.; Wilson, D. M.; Wood, A. Organic synthesis provides opportunities to transform drug discovery. Nat. Chem. 2018, 10 (4), 383-394, 10.1038/s41557-018-0021-z
243. Pennington, L. D.; Moustakas, D. T. The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization. J. Med. Chem. 2017, 60 (9), 3552-3579, 10.1021/acs.jmedchem.6b01807
244. Leung, C. S.; Leung, S. S.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein-ligand binding. J. Med. Chem. 2012, 55 (9), 4489-4500, 10.1021/jm3003697
245. Schonherr, H.; Cernak, T. Profound methyl effects in drug discovery and a call for new C-H methylation reactions. Angew. Chem., Int. Ed. 2013, 52 (47), 12256-12267, 10.1002/anie.201303207
246. Kuntz, K. W.; Campbell, J. E.; Keilhack, H.; Pollock, R. M.; Knutson, S. K.; Porter-Scott, M.; Richon, V. M.; Sneeringer, C. J.; Wigle, T. J.; Allain, C. J.; Majer, C. R.; Moyer, M. P.; Copeland, R. A.; Chesworth, R. The importance of being Me: magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat. J. Med. Chem. 2016, 59 (4), 1556-1564, 10.1021/acs.jmedchem.5b01501
247. Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.; Meanwell, N. A. Applications of fluorine in medicinal chemistry. J. Med. Chem. 2015, 58 (21), 8315-8359, 10.1021/acs.jmedchem.5b00258
248. Pettersson, M.; Hou, X.; Kuhn, M.; Wager, T. T.; Kauffman, G. W.; Verhoest, P. R. Quantitative Assessment of the impact of fluorine substitution on p-glycoprotein (p-gp) mediated efflux, permeability, lipophilicity, and metabolic stability. J. Med. Chem. 2016, 59 (11), 5284-5296, 10.1021/acs.jmedchem.6b00027
249. Mao, F.; Ni, W.; Xu, X.; Wang, H.; Wang, J.; Ji, M.; Li, J. Chemical structure-related druglike criteria of global approved drugs. Molecules 2016, 21 (1), 75, 10.3390/molecules21010075
250. Springthorpe, B.; Bailey, A.; Barton, P.; Birkinshaw, T. N.; Bonnert, R. V.; Brown, R. C.; Chapman, D.; Dixon, J.; Guile, S. D.; Humphries, R. G.; Hunt, S. F.; Ince, F.; Ingall, A. H.; Kirk, I. P.; Leeson, P. D.; Leff, P.; Lewis, R. J.; Martin, B. P.; McGinnity, D. F.; Mortimore, M. P.; Paine, S. W.; Pairaudeau, G.; Patel, A.; Rigby, A. J.; Riley, R. J.; Teobald, B. J.; Tomlinson, W.; Webborn, P. J.; Willis, P. A. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 2007, 17 (21), 6013-6018, 10.1016/j.bmcl.2007.07.057
251. Lee, K. L.; Ambler, C. M.; Anderson, D. R.; Boscoe, B. P.; Bree, A. G.; Brodfuehrer, J. I.; Chang, J. S.; Choi, C.; Chung, S.; Curran, K. J.; Day, J. E.; Dehnhardt, C. M.; Dower, K.; Drozda, S. E.; Frisbie, R. K.; Gavrin, L. K.; Goldberg, J. A.; Han, S.; Hegen, M.; Hepworth, D.; Hope, H. R.; Kamtekar, S.; Kilty, I. C.; Lee, A.; Lin, L. L.; Lovering, F. E.; Lowe, M. D.; Mathias, J. P.; Morgan, H. M.; Murphy, E. A.; Papaioannou, N.; Patny, A.; Pierce, B. S.; Rao, V. R.; Saiah, E.; Samardjiev, I. J.; Samas, B. M.; Shen, M. W. H.; Shin, J. H.; Soutter, H. H.; Strohbach, J. W.; Symanowicz, P. T.; Thomason, J. R.; Trzupek, J. D.; Vargas, R.; Vincent, F.; Yan, J.; Zapf, C. W.; Wright, S. W. Discovery of clinical candidate 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoli ne-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design. J. Med. Chem. 2017, 60 (13), 5521-5542, 10.1021/acs.jmedchem.7b00231
252. McCoull, W.; Abrams, R. D.; Anderson, E.; Blades, K.; Barton, P.; Box, M.; Burgess, J.; Byth, K.; Cao, Q.; Chuaqui, C.; Carbajo, R. J.; Cheung, T.; Code, E.; Ferguson, A. D.; Fillery, S.; Fuller, N. O.; Gangl, E.; Gao, N.; Grist, M.; Hargreaves, D.; Howard, M. R.; Hu, J.; Kemmitt, P. D.; Nelson, J. E.; O'Connell, N.; Prince, D. B.; Raubo, P.; Rawlins, P. B.; Robb, G. R.; Shi, J.; Waring, M. J.; Whittaker, D.; Wylot, M.; Zhu, X. Discovery of pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) binders and optimization to high affinity macrocyclic inhibitors. J. Med. Chem. 2017, 60 (10), 4386-4402, 10.1021/acs.jmedchem.7b00359
253. Millan, D. S.; Kayser-Bricker, K. J.; Martin, M. W.; Talbot, A. C.; Schiller, S. E. R.; Herbertz, T.; Williams, G. L.; Luke, G. P.; Hubbs, S.; Alvarez Morales, M. A.; Cardillo, D.; Troccolo, P.; Mendes, R. L.; McKinnon, C. Design and optimization of benzopiperazines as potent inhibitors of BET bromodomains. ACS Med. Chem. Lett. 2017, 8 (8), 847-852, 10.1021/acsmedchemlett.7b00191
254. Smith, C. R.; Dougan, D. R.; Komandla, M.; Kanouni, T.; Knight, B.; Lawson, J. D.; Sabat, M.; Taylor, E. R.; Vu, P.; Wyrick, C. Fragment-based discovery of a small molecule inhibitor of bruton's tyrosine kinase. J. Med. Chem. 2015, 58 (14), 5437-5444, 10.1021/acs.jmedchem.5b00734
255. McDaniel, K. F.; Wang, L.; Soltwedel, T.; Fidanze, S. D.; Hasvold, L. A.; Liu, D.; Mantei, R. A.; Pratt, J. K.; Sheppard, G. S.; Bui, M. H.; Faivre, E. J.; Huang, X.; Li, L.; Lin, X.; Wang, R.; Warder, S. E.; Wilcox, D.; Albert, D. H.; Magoc, T. J.; Rajaraman, G.; Park, C. H.; Hutchins, C. W.; Shen, J. J.; Edalji, R. P.; Sun, C. C.; Martin, R.; Gao, W.; Wong, S.; Fang, G.; Elmore, S. W.; Shen, Y.; Kati, W. M. Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J. Med. Chem. 2017, 60 (20), 8369-8384, 10.1021/acs.jmedchem.7b00746
256. Imaeda, Y.; Tokuhara, H.; Fukase, Y.; Kanagawa, R.; Kajimoto, Y.; Kusumoto, K.; Kondo, M.; Snell, G.; Behnke, C. A.; Kuroita, T. Discovery of TAK-272: a novel, potent, and orally active renin inhibitor. ACS Med. Chem. Lett. 2016, 7 (10), 933-938, 10.1021/acsmedchemlett.6b00251
257. Lorthiois, E.; Anderson, K.; Vulpetti, A.; Rogel, O.; Cumin, F.; Ostermann, N.; Steinbacher, S.; Mac Sweeney, A.; Delgado, O.; Liao, S. M.; Randl, S.; Rudisser, S.; Dussauge, S.; Fettis, K.; Kieffer, L.; de Erkenez, A.; Yang, L.; Hartwieg, C.; Argikar, U. A.; La Bonte, L. R.; Newton, R.; Kansara, V.; Flohr, S.; Hommel, U.; Jaffee, B.; Maibaum, J. Discovery of highly potent and selective small-molecule reversible factor D Inhibitors demonstrating alternative complement pathway inhibition in vivo. J. Med. Chem. 2017, 60 (13), 5717-5735, 10.1021/acs.jmedchem.7b00425
258. Kung, P. P.; Rui, E.; Bergqvist, S.; Bingham, P.; Braganza, J.; Collins, M.; Cui, M.; Diehl, W.; Dinh, D.; Fan, C.; Fantin, V. R.; Gukasyan, H. J.; Hu, W.; Huang, B.; Kephart, S.; Krivacic, C.; Kumpf, R. A.; Li, G.; Maegley, K. A.; McAlpine, I.; Nguyen, L.; Ninkovic, S.; Ornelas, M.; Ryskin, M.; Scales, S.; Sutton, S.; Tatlock, J.; Verhelle, D.; Wang, F.; Wells, P.; Wythes, M.; Yamazaki, S.; Yip, B.; Yu, X.; Zehnder, L.; Zhang, W. G.; Rollins, R. A.; Edwards, M. Design and synthesis of pyridone-containing 3,4-dihydroisoquinoline-1(2H)-ones as a novel class of enhancer of zeste homolog 2 (EZH2) inhibitors. J. Med. Chem. 2016, 59 (18), 8306-8325, 10.1021/acs.jmedchem.6b00515
259. Handlon, A. L.; Schaller, L. T.; Leesnitzer, L. M.; Merrihew, R. V.; Poole, C.; Ulrich, J. C.; Wilson, J. W.; Cadilla, R.; Turnbull, P. Optimizing ligand efficiency of selective androgen receptor modulators (SARMs). ACS Med. Chem. Lett. 2016, 7 (1), 83-88, 10.1021/acsmedchemlett.5b00377
260. Futatsugi, K.; Kung, D. W.; Orr, S. T.; Cabral, S.; Hepworth, D.; Aspnes, G.; Bader, S.; Bian, J.; Boehm, M.; Carpino, P. A.; Coffey, S. B.; Dowling, M. S.; Herr, M.; Jiao, W.; Lavergne, S. Y.; Li, Q.; Clark, R. W.; Erion, D. M.; Kou, K.; Lee, K.; Pabst, B. A.; Perez, S. M.; Purkal, J.; Jorgensen, C. C.; Goosen, T. C.; Gosset, J. R.; Niosi, M.; Pettersen, J. C.; Pfefferkorn, J. A.; Ahn, K.; Goodwin, B. Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2). J. Med. Chem. 2015, 58 (18), 7173-7185, 10.1021/acs.jmedchem.5b01006
261. Bagdanoff, J. T.; Jain, R.; Han, W.; Poon, D.; Lee, P. S.; Bellamacina, C.; Lindvall, M. Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase. Bioorg. Med. Chem. Lett. 2015, 25 (17), 3626-3629, 10.1016/j.bmcl.2015.06.063
262. Mandal, M.; Tan, Z.; Madsen-Duggan, C.; Buevich, A. V.; Caldwell, J. P.; Dejesus, R.; Flattery, A.; Garlisi, C. G.; Gill, C.; Ha, S. N.; Ho, G.; Koseoglu, S.; Labroli, M.; Basu, K.; Lee, S. H.; Liang, L.; Liu, J.; Mayhood, T.; McGuinness, D.; McLaren, D. G.; Wen, X.; Parmee, E.; Rindgen, D.; Roemer, T.; Sheth, P.; Tawa, P.; Tata, J.; Yang, C.; Yang, S. W.; Xiao, L.; Wang, H.; Tan, C.; Tang, H.; Walsh, P.; Walsh, E.; Wu, J.; Su, J. Can we make small molecules lean? optimization of a highly lipophilic TarO inhibitor. J. Med. Chem. 2017, 60 (9), 3851-3865, 10.1021/acs.jmedchem.7b00113
263. Stepan, A. F.; Claffey, M. M.; Reese, M. R.; Balan, G.; Barreiro, G.; Barricklow, J.; Bohanon, M. J.; Boscoe, B. P.; Cappon, G. D.; Chenard, L. K.; Cianfrogna, J.; Chen, L.; Coffman, K. J.; Drozda, S. E.; Dunetz, J. R.; Ghosh, S.; Hou, X.; Houle, C.; Karki, K.; Lazzaro, J. T.; Mancuso, J. Y.; Marcek, J. M.; Miller, E. L.; Moen, M. A.; O'Neil, S.; Sakurada, I.; Skaddan, M.; Parikh, V.; Smith, D. L.; Trapa, P.; Tuttle, J. B.; Verhoest, P. R.; Walker, D. P.; Won, A.; Wright, A. S.; Whritenour, J.; Zasadny, K.; Zaleska, M. M.; Zhang, L.; Shaffer, C. L. Discovery and characterization of (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9 H)-one (PF-06462894), an alkyne-lacking metabotropic glutamate receptor 5 negative allosteric modulator profiled in both rat and nonhuman primates. J. Med. Chem. 2017, 60 (18), 7764-7780, 10.1021/acs.jmedchem.7b00604
264. Skerratt, S. E.; Andrews, M.; Bagal, S. K.; Bilsland, J.; Brown, D.; Bungay, P. J.; Cole, S.; Gibson, K. R.; Jones, R.; Morao, I.; Nedderman, A.; Omoto, K.; Robinson, C.; Ryckmans, T.; Skinner, K.; Stupple, P.; Waldron, G. The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain. J. Med. Chem. 2016, 59 (22), 10084-10099, 10.1021/acs.jmedchem.6b00850
265. Hoyt, S. B.; Park, M. K.; London, C.; Xiong, Y.; Tata, J.; Bennett, D. J.; Cooke, A.; Cai, J.; Carswell, E.; Robinson, J.; MacLean, J.; Brown, L.; Belshaw, S.; Clarkson, T. R.; Liu, K.; Liang, G. B.; Struthers, M.; Cully, D.; Wisniewski, T.; Ren, N.; Bopp, C.; Sok, A.; Cai, T. Q.; Stribling, S.; Pai, L. Y.; Ma, X.; Metzger, J.; Verras, A.; McMasters, D.; Chen, Q.; Tung, E.; Tang, W.; Salituro, G.; Buist, N.; Kuethe, J.; Rivera, N.; Clemas, J.; Zhou, G.; Gibson, J.; Maxwell, C. A.; Lassman, M.; McLaughlin, T.; Castro-Perez, J.; Szeto, D.; Forrest, G.; Hajdu, R.; Rosenbach, M.; Ali, A. Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys. ACS Med. Chem. Lett. 2015, 6 (5), 573-578, 10.1021/acsmedchemlett.5b00054
266. Curtin, M. L.; Pliushchev, M. A.; Li, H. Q.; Torrent, M.; Dietrich, J. D.; Jakob, C. G.; Zhu, H.; Zhao, H.; Wang, Y.; Ji, Z.; Clark, R. F.; Sarris, K. A.; Selvaraju, S.; Shaw, B.; Algire, M. A.; He, Y.; Richardson, P. L.; Sweis, R. F.; Sun, C.; Chiang, G. G.; Michaelides, M. R. SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding. Bioorg. Med. Chem. Lett. 2017, 27 (7), 1576-1583, 10.1016/j.bmcl.2017.02.030
267. Zhou, H. J.; Wang, J.; Yao, B.; Wong, S.; Djakovic, S.; Kumar, B.; Rice, J.; Valle, E.; Soriano, F.; Menon, M. K.; Madriaga, A.; Kiss von Soly, S.; Kumar, A.; Parlati, F.; Yakes, F. M.; Shawver, L.; Le Moigne, R.; Anderson, D. J.; Rolfe, M.; Wustrow, D. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083). J. Med. Chem. 2015, 58 (24), 9480-9497, 10.1021/acs.jmedchem.5b01346
268. Castanedo, G. M.; Blaquiere, N.; Beresini, M.; Bravo, B.; Brightbill, H.; Chen, J.; Cui, H. F.; Eigenbrot, C.; Everett, C.; Feng, J.; Godemann, R.; Gogol, E.; Hymowitz, S.; Johnson, A.; Kayagaki, N.; Kohli, P. B.; Knuppel, K.; Kraemer, J.; Kruger, S.; Loke, P.; McEwan, P.; Montalbetti, C.; Roberts, D. A.; Smith, M.; Steinbacher, S.; Sujatha-Bhaskar, S.; Takahashi, R.; Wang, X.; Wu, L. C.; Zhang, Y.; Staben, S. T. Structure-Based design of tricyclic NF-kappaB inducing kinase (NIK) inhibitors that have high selectivity over phosphoinositide-3-kinase (PI3K). J. Med. Chem. 2017, 60 (2), 627-640, 10.1021/acs.jmedchem.6b01363
269. Takahashi, B.; Funami, H.; Shibata, M.; Maruoka, H.; Koyama, M.; Kanki, S.; Muto, T. Structural Optimization of ghrelin receptor inverse agonists to improve lipophilicity and avoid mechanism-based CYP3A4 inactivation. Chem. Pharm. Bull. 2015, 63 (10), 825-832, 10.1248/cpb.c15-00285
270. Pero, J. E.; Rossi, M. A.; Kelly, M. J., 3rd; Lehman, H. D.; Layton, M. E.; Garbaccio, R. M.; O'Brien, J. A.; Magliaro, B. C.; Uslaner, J. M.; Huszar, S. L.; Fillgrove, K. L.; Tang, C.; Kuo, Y.; Joyce, L. A.; Sherer, E. C.; Jacobson, M. A. Optimization of novel aza-benzimidazolone mGluR2 PAMs with respect to LLE and PK properties and mitigation of CYP TDI. ACS Med. Chem. Lett. 2016, 7 (3), 312-317, 10.1021/acsmedchemlett.5b00459
271. Doyle, K.; Lonn, H.; Kack, H.; Van de Poel, A.; Swallow, S.; Gardiner, P.; Connolly, S.; Root, J.; Wikell, C.; Dahl, G.; Stenvall, K.; Johannesson, P. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J. Med. Chem. 2016, 59 (20), 9457-9472, 10.1021/acs.jmedchem.6b01127
272. Patel, S.; Meilandt, W. J.; Erickson, R. I.; Chen, J.; Deshmukh, G.; Estrada, A. A.; Fuji, R. N.; Gibbons, P.; Gustafson, A.; Harris, S. F.; Imperio, J.; Liu, W.; Liu, X.; Liu, Y.; Lyssikatos, J. P.; Ma, C.; Yin, J.; Lewcock, J. W.; Siu, M. Selective inhibitors of dual leucine zipper kinase (DLK, MAP3K12) with activity in a model of Alzheimer's disease. J. Med. Chem. 2017, 60 (19), 8083-8102, 10.1021/acs.jmedchem.7b00843
273. Umei, K.; Nishigaya, Y.; Tatani, K.; Kohno, Y.; Tanaka, N.; Seto, S. Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP1 receptor antagonists. Bioorg. Med. Chem. 2017, 25 (13), 3406-3430, 10.1016/j.bmc.2017.04.028
274. Nishida, H.; Arikawa, Y.; Hirase, K.; Imaeda, T.; Inatomi, N.; Hori, Y.; Matsukawa, J.; Fujioka, Y.; Hamada, T.; Iida, M.; Nishitani, M.; Imanishi, A.; Fukui, H.; Itoh, F.; Kajino, M. Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action. Bioorg. Med. Chem. 2017, 25 (13), 3298-3314, 10.1016/j.bmc.2017.04.014
275. Hoveyda, H. R.; Fraser, G. L.; Dutheuil, G.; El Bousmaqui, M.; Korac, J.; Lenoir, F.; Lapin, A.; Noel, S. Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (part II). ACS Med. Chem. Lett. 2015, 6 (7), 736-740, 10.1021/acsmedchemlett.5b00117
276. Díaz, J. L.; Corbera, J.; Martínez, D.; Bordas, M.; Sicre, C.; Pascual, R.; Pretel, M. J.; Marín, A. P.; Montero, A.; Dordal, A.; Alvarez, I.; Almansa, C. Pyrazolo[3,4-d]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4. MedChemComm 2017, 8 (6), 1246-1254, 10.1039/C7MD00078B
277. Pike, K. G.; Morris, J.; Ruston, L.; Pass, S. L.; Greenwood, R.; Williams, E. J.; Demeritt, J.; Culshaw, J. D.; Gill, K.; Pass, M.; Finlay, M. R.; Good, C. J.; Roberts, C. A.; Currie, G. S.; Blades, K.; Eden, J. M.; Pearson, S. E. Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2. J. Med. Chem. 2015, 58 (5), 2326-2349, 10.1021/jm501778s
278. Yamada, K.; Levell, J.; Yoon, T.; Kohls, D.; Yowe, D.; Rigel, D. F.; Imase, H.; Yuan, J.; Yasoshima, K.; DiPetrillo, K.; Monovich, L.; Xu, L.; Zhu, M.; Kato, M.; Jain, M.; Idamakanti, N.; Taslimi, P.; Kawanami, T.; Argikar, U. A.; Kunjathoor, V.; Xie, X.; Yagi, Y. I.; Iwaki, Y.; Robinson, Z.; Park, H. M. Optimization of allosteric with-no-lysine (WNK) kinase inhibitors and efficacy in rodent hypertension models. J. Med. Chem. 2017, 60 (16), 7099-7107, 10.1021/acs.jmedchem.7b00708
279. Hansen, S. V.; Christiansen, E.; Urban, C.; Hudson, B. D.; Stocker, C. J.; Due-Hansen, M. E.; Wargent, E. T.; Shimpukade, B.; Almeida, R.; Ejsing, C. S.; Cawthorne, M. A.; Kassack, M. U.; Milligan, G.; Ulven, T. Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area, and robust in vivo efficacy. J. Med. Chem. 2016, 59 (6), 2841-2846, 10.1021/acs.jmedchem.5b01962
280. Fukunaga, K.; Sakai, D.; Watanabe, K.; Nakayama, K.; Kohara, T.; Tanaka, H.; Sunada, S.; Nabeno, M.; Okamoto, M.; Saito, K.; Eguchi, J.; Mori, A.; Tanaka, S.; Inazawa, K.; Horikawa, T. Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3beta inhibitors for Alzheimer's disease. Bioorg. Med. Chem. Lett. 2015, 25 (5), 1086-1091, 10.1016/j.bmcl.2015.01.005
281. Degorce, S. L.; Boyd, S.; Curwen, J. O.; Ducray, R.; Halsall, C. T.; Jones, C. D.; Lach, F.; Lenz, E. M.; Pass, M.; Pass, S.; Trigwell, C. Discovery of a potent, selective, orally bioavailable, and efficacious novel 2-(pyrazol-4-ylamino)-pyrimidine inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). J. Med. Chem. 2016, 59 (10), 4859-4866, 10.1021/acs.jmedchem.6b00203
282. Siu, T.; Brubaker, J.; Fuller, P.; Torres, L.; Zeng, H.; Close, J.; Mampreian, D. M.; Shi, F.; Liu, D.; Fradera, X.; Johnson, K.; Bays, N.; Kadic, E.; He, F.; Goldenblatt, P.; Shaffer, L.; Patel, S. B.; Lesburg, C. A.; Alpert, C.; Dorosh, L.; Deshmukh, S. V.; Yu, H.; Klappenbach, J.; Elwood, F.; Dinsmore, C. J.; Fernandez, R.; Moy, L.; Young, J. R. The discovery of 3-((4-chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1 H-pyrazole-4-carboxamide, a highly ligand efficient and efficacious janus kinase 1 selective inhibitor with favorable pharmacokinetic properties. J. Med. Chem. 2017, 60 (23), 9676-9690, 10.1021/acs.jmedchem.7b01135
283. Rene, O.; Fauber, B. P.; Barnard, A.; Chapman, K.; Deng, Y.; Eidenschenk, C.; Everett, C.; Gobbi, A.; Johnson, A. R.; La, H.; Norman, M.; Salmon, G.; Summerhill, S.; Wong, H. Discovery of oxa-sultams as RORc inverse agonists showing reduced lipophilicity, improved selectivity and favorable ADME properties. Bioorg. Med. Chem. Lett. 2016, 26 (18), 4455-4461, 10.1016/j.bmcl.2016.07.081
284. Lee, E. C.; Futatsugi, K.; Arcari, J. T.; Bahnck, K.; Coffey, S. B.; Derksen, D. R.; Kalgutkar, A. S.; Loria, P. M.; Sharma, R. Optimization of amide-based EP3 receptor antagonists. Bioorg. Med. Chem. Lett. 2016, 26 (11), 2670-2675, 10.1016/j.bmcl.2016.04.009
285. Davoren, J. E.; Lee, C. W.; Garnsey, M.; Brodney, M. A.; Cordes, J.; Dlugolenski, K.; Edgerton, J. R.; Harris, A. R.; Helal, C. J.; Jenkinson, S.; Kauffman, G. W.; Kenakin, T. P.; Lazzaro, J. T.; Lotarski, S. M.; Mao, Y.; Nason, D. M.; Northcott, C.; Nottebaum, L.; O'Neil, S. V.; Pettersen, B.; Popiolek, M.; Reinhart, V.; Salomon-Ferrer, R.; Steyn, S. J.; Webb, D.; Zhang, L.; Grimwood, S. Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): evaluation of efficacy and cholinergic side effects. J. Med. Chem. 2016, 59 (13), 6313-6328, 10.1021/acs.jmedchem.6b00544
286. Lemurell, M.; Ulander, J.; Winiwarter, S.; Dahlen, A.; Davidsson, O.; Emtenas, H.; Broddefalk, J.; Swanson, M.; Hovdal, D.; Plowright, A. T.; Pettersen, A.; Ryden-Landergren, M.; Barlind, J.; Llinas, A.; Herslof, M.; Drmota, T.; Sigfridsson, K.; Moses, S.; Whatling, C. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases. J. Med. Chem. 2015, 58 (2), 897-911, 10.1021/jm501531v
287. Johnson, T. W.; Richardson, P. F.; Bailey, S.; Brooun, A.; Burke, B. J.; Collins, M. R.; Cui, J. J.; Deal, J. G.; Deng, Y. L.; Dinh, D.; Engstrom, L. D.; He, M.; Hoffman, J.; Hoffman, R. L.; Huang, Q.; Kania, R. S.; Kath, J. C.; Lam, H.; Lam, J. L.; Le, P. T.; Lingardo, L.; Liu, W.; McTigue, M.; Palmer, C. L.; Sach, N. W.; Smeal, T.; Smith, G. L.; Stewart, A. E.; Timofeevski, S.; Zhu, H.; Zhu, J.; Zou, H. Y.; Edwards, M. P. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J. Med. Chem. 2014, 57 (11), 4720-4744, 10.1021/jm500261q
288. Yamada, K.; Brousseau, M.; Honma, W.; Iimura, A.; Imase, H.; Iwaki, Y.; Kawanami, T.; LaSala, D.; Liang, G.; Mitani, H.; Nonomura, K.; Ohmori, O.; Pan, M.; Rigel, D. F.; Umemura, I.; Yasoshima, K.; Zhu, G.; Mogi, M. Discovery of a novel piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) that retains activity in hypertriglyceridemic plasma. J. Med. Chem. 2017, 60 (20), 8466-8481, 10.1021/acs.jmedchem.7b00900
289. Higueruelo, A. P.; Schreyer, A.; Bickerton, G. R.; Blundell, T. L.; Pitt, W. R. What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics?. PLoS One 2012, 7 (12), e51742, 10.1371/journal.pone.0051742
290. Cumming, J. G.; Davis, A. M.; Muresan, S.; Haeberlein, M.; Chen, H. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discovery 2013, 12 (12), 948-962, 10.1038/nrd4128
291. Aliagas, I.; Berger, R.; Goldberg, K.; Nishimura, R. T.; Reilly, J.; Richardson, P.; Richter, D.; Sherer, E. C.; Sparling, B. A.; Bryan, M. C. Sustainable practices in medicinal chemistry part 2: green by design. J. Med. Chem. 2017, 60 (14), 5955-5968, 10.1021/acs.jmedchem.6b01837
292. Stratton, C. F.; Newman, D. J.; Tan, D. S. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorg. Med. Chem. Lett. 2015, 25 (21), 4802-4807, 10.1016/j.bmcl.2015.07.014
293. Camp, D.; Garavelas, A.; Campitelli, M. Analysis of physicochemical properties for drugs of natural origin. J. Nat. Prod. 2015, 78 (6), 1370-1382, 10.1021/acs.jnatprod.5b00255
294. Harvey, A. L.; Edrada-Ebel, R.; Quinn, R. J. The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discovery 2015, 14 (2), 111-129, 10.1038/nrd4510
295. Over, B.; Wetzel, S.; Grutter, C.; Nakai, Y.; Renner, S.; Rauh, D.; Waldmann, H. Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem. 2013, 5 (1), 21-28, 10.1038/nchem.1506
296. Rizzo, S.; Wakchaure, V.; Waldmann, H. Natural product-derived and natural product-inspired compound collections. In Natural Products in Medicinal Chemistry; Wiley-VCH Verlag GmbH & Co. KGaA, 2014; pp 43-80, DOI: 10.1002/9783527676545.ch02.
297. Cheshire, D. R. How well do medicinal chemists learn from experience?. Drug Discovery Today 2011, 16 (17-18), 817-821, 10.1016/j.drudis.2011.06.005
298. Tresadern, G.; Rombouts, F. J. R.; Oehlrich, D.; Macdonald, G.; Trabanco, A. A. Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. Drug Discovery Today 2017, 22 (10), 1478-1488, 10.1016/j.drudis.2017.05.013
299. Grime, K. H.; Barton, P.; McGinnity, D. F. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics. Mol. Pharmaceutics 2013, 10 (4), 1191-1206, 10.1021/mp300476z
300. Bueters, T.; Gibson, C.; Visser, S. A. Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery. Future Med. Chem. 2015, 7 (17), 2351-2369, 10.4155/fmc.15.143
301. Copeland, R. A. The drug-target residence time model: a 10-year retrospective. Nat. Rev. Drug Discovery 2016, 15, 87-95, 10.1038/nrd.2015.18
302. Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. J. Med. Chem. 2018, 61 (2), 444-452, 10.1021/acs.jmedchem.7b01272
303. Schneider, G. Automating drug discovery. Nat. Rev. Drug Discovery 2018, 17 (2), 97-113, 10.1038/nrd.2017.232
304. Klucznik, T.; Mikulak-Klucznik, B.; McCormack, M. P.; Lima, H.; Szymkuć, S.; Bhowmick, M.; Molga, K.; Zhou, Y.; Rickershauser, L.; Gajewska, E. P.; Toutchkine, A.; Dittwald, P.; Startek, M. P.; Kirkovits, G. J.; Roszak, R.; Adamski, A.; Sieredzińska, B.; Mrksich, M.; Trice, S. L. J.; Grzybowski, B. A. Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory. Chem. 2018, 4 (3), 522-532, 10.1016/j.chempr.2018.02.002
305. Hu, Y.; Bajorath, J. Entering the "big data" era in medicinal chemistry: molecular promiscuity analysis revisited. Future Sci. OA 2017, 3 (2), FSO179, 10.4155/fsoa-2017-0001
306. Johnstone, C. Medicinal chemistry matters-a call for discipline in our discipline. Drug Discovery Today 2012, 17 (11-12), 538-543, 10.1016/j.drudis.2012.01.010